

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Pros and cons of gastric bypass surgery in obese individuals with type 2 diabetes: nationwide, matched, observational cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023882
Article Type:	Research
Date Submitted by the Author:	01-May-2018
Complete List of Authors:	Liakopoulos, Vasileios; Goteborgs Universitet, Department of Molecular and Clinical Medicine; Sahlgrenska universitetssjukhuset, Department of Medical Clinic Franzén, Stefan; Centre of Registers Västra Götaland; Goteborgs Universitet, Health Metrics Unit, Sahlgrenska Academy Svensson, Ann-Marie; Centre of Registers in Region Västra Götaland; Goteborgs Universitet, Department of Molecular and Clinical Medicine Miftaraj, Mervete; Center of Registers in Region Västra Götaland Ottosson, Johan ; Orebro Universitet, Department of Surgery, Faculty of Medicine and Health Näslund, Ingmar; Orebro Universitet, Department of Surgery, Faculty of Medicine and Health Gudbjornsdottir, Soffia; Goteborgs Universitet; National Diabetes Register, Centre of Registers Eliasson, Björn; University of Gothenburg, Department of Medical Clinic; Goteborgs Universitet, Department of Molecular and Clinical Medicine
Keywords:	DIABETES & ENDOCRINOLOGY, SURGERY, Adverse events < THERAPEUTICS

SCHOLARONE™  
Manuscripts



**TITLE PAGE**

**Complete title:** Pros and cons of gastric bypass surgery in obese individuals with type 2 diabetes: nationwide, matched, observational cohort study

**Authors:**

Vasileios Liakopoulos MSc<sup>1,2</sup>

Stefan Franzén PhD<sup>3,4</sup>

Ann-Marie Svensson PhD<sup>1,3</sup>

Mervete Miftaraj MSc<sup>3</sup>

Johan Ottosson, Associate professor, PhD

Ingmar Näslund, Associate professor, PhD

Soffia Gudbjörnsdottir, Professor, PhD<sup>1,3</sup>

Björn Eliasson, Professor, PhD<sup>1,2</sup>

**Affiliations:**

1 Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden

2 Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

3 National Diabetes Register, Centre of Registers, Gothenburg, Sweden

4 Health Metrics Unit, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

5 Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

**Corresponding author:** Vasileios Liakopoulos, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

Address SE- 413 45, Gothenburg, Sweden

Phone +46 76 112 81 32

1  
2  
3 E-mail vasileios.liakopoulos@vgregion.se  
4

5 **Keywords:** diabetes mellitus; obesity; bariatric surgery; postoperative complications; adverse  
6 effects  
7  
8

9 **Word count:** 2640  
10

11 **Number of tables:** 2  
12

13 **Number of figures:** 2  
14  
15

16  
17  
18  
19 **ABSTRACT** Word count: 300  
20

21  
22 **Objectives:** Long-term effects of gastric bypass (GBP) surgery have been presented in  
23 observational and randomized studies, but there are only limited data for obese persons with type  
24 2 diabetes (T2DM), regarding postoperative complications.  
25  
26  
27  
28

29  
30 **Design:** This is a nationwide observational study based on two quality registers in Sweden: the  
31 National Diabetes Register (NDR) and the Scandinavian Obesity Surgery Register (SOReg), as  
32 well other national databases.  
33  
34  
35  
36

37  
38 **Setting:** After merging the data, we matched individuals with T2DM who had undergone GBP  
39 with those not surgically treated for obesity on propensity score, based on sex, age, BMI and  
40 calendar time. The risks of postoperative outcomes (rehospitalizations) were assessed using Cox  
41 regression models.  
42  
43  
44  
45  
46

47 **Participants:** We identified 5,321 patients with T2DM in the SOReg, as well as 5,321 matched  
48 controls in the NDR, aged 18-65 years, with BMI >27,5 kg/m<sup>2</sup> and followed for up to 9 years.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

1  
2  
3 **Primary and secondary outcome measures:** We assessed risks for all-cause mortality and  
4 hospitalizations for cardiovascular disease, severe kidney disease, as well as for surgical and  
5 other medical conditions.  
6  
7  
8

9  
10 **Results:** We confirmed lower risks of all-cause mortality (49%) and cardiovascular disease  
11 (34%), found positive effects for severe kidney disease but demonstrated significantly increased  
12 risks (2 to 9-fold) of several short-term complications after GBP, such as abdominal pain and  
13 gastrointestinal conditions, frequently requiring surgical procedures, apart from reconstructive  
14 plastic surgery. Long-term, the risk of anemia was 92% higher, malnutrition developed  
15 approximately 3 times as often, psychiatric diagnoses were 33% more frequent and alcohol abuse  
16 was 3 times as great as in the control group.  
17  
18  
19

20 **Conclusions:** This nationwide study confirms the benefits and describes the panorama of adverse  
21 events after bariatric surgery in obese persons with T2DM. Long-term postoperative monitoring  
22 and support, and possibly also better selection of patients by appropriate specialists in  
23 interdisciplinary settings, should be provided to optimize the outcomes.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- Major strength of our study is the unique and nationwide character of our population with type 2 diabetes that received gastric bypass operation.
- The high data reliability as well the external validity allow the generalizing of our results to similar developed countries using the same criteria and contraindications for bariatric surgery and quality of care.
- Our nonrandomized observational study may be limited by some minor differences between the matched groups on the propensity score.
- We tried to eliminate major confounders by careful matching between the two groups as well with an adjusted Cox regression model, however we cannot exclude underlying residual confounders.
- We studied effects and postoperative events after gastric bypass in in-patients (rehospitalizations) leaving unassessed a large proportion of out-patients visiting the primary care.

## MAIN TEXT

### Introduction

The most effective method for ensuring long-term weight reduction in obese individuals as well as beneficial effects on mortality, cardiovascular disease (CVD) and CV risk factors is bariatric surgery, Roux-en-Y gastric bypass (GBP) in particular (1-3). These effects of GBP have also been shown in patients with type 2 diabetes (T2DM) in both observational (4-6) and randomized control trials (7-9) under different follow-up periods. However, it has also been demonstrated in cohorts with a low proportion of individuals with diabetes that GBP is associated with postoperative complications and readmission rates from 0.6% to 11.3% (10-13), as well as long-term adverse outcomes such as hypoglycemia (7), anemia, nutritional deficiencies (14), gallstones (3), depression (15), suicide and non-fatal self-harm (16) and alcohol problems (17).

Only few reports have addressed the long-term incidence of complications in obese patients with T2DM who have undergone bariatric surgery. The Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently (STAMPEDE) study reported adverse events of GBP and sleeve gastrectomy compared to conventional medical therapy, but only in 142 individuals with T2DM randomized at a single center with follow-up period up to 5 years (7). Similarly, the Diabetes Surgery Study recently reported clinical effects and adverse events after GBP or lifestyle–medical management in 120 individuals after 5 years (18). Larger prospective studies such as Swedish Obese Subjects (SOS) study (1) and large American observational studies with broad samples (11, 19) have addressed postoperative outcomes of GBP or sleeve gastrectomy, but with only a small proportion of patients who have T2DM.

1  
2  
3 We recently conducted a nationwide observational study of individuals with T2DM who  
4  
5 underwent GBP compared with matched individuals and reported beneficial effects on overall  
6  
7 mortality and cardiovascular events (4), but we did not address short-term or long-term adverse  
8  
9 effects. The objective of this observational cohort study is therefore to identify clinical benefits as  
10  
11 well as a wide spectrum of early postoperative, as well long-term, adverse effects of GBP for up  
12  
13 to 9 years in individuals with T2DM compared to obese individuals who have not received  
14  
15 surgical treatment.  
16  
17  
18  
19

## 20 **Research Design and Methods**

21  
22  
23 This study is based on two nationwide quality registers in Sweden: the National Diabetes  
24  
25 Register (NDR) and the Scandinavian Obesity Surgery Register (SOReg), as well as linked data  
26  
27 from the Swedish Inpatient Register, the Cause of Death Register and the Statistics Sweden. All  
28  
29 these databases have previously been described and validated (20, 21). The NDR is a quality  
30  
31 register tool that provides nearly full coverage (90% for T2DM and 95% for T1DM) of Swedes  
32  
33 with diabetes since 1996. SOReg started in 2007 as a quality and research register. Since 2010, it  
34  
35 has covered virtually all bariatric procedures in Sweden. All bariatric centers report to the register  
36  
37 (surgical complications, postoperative reports and longitudinal effects).  
38  
39  
40  
41  
42

## 43 **Patient and Public Involvement**

44  
45  
46 All individuals provided verbal informed consent before being included in the NDR and SOReg  
47  
48 databases and that data could be used for research. They did not, however, provide consent for  
49  
50 this specific study. Patients have the rights to deny being included in studies by the time of  
51  
52 register. Furthermore, data and patients' personal identity numbers identified and replaced by  
53  
54 serial numbers in the National Board of Health and Welfare, so patients had not direct  
55  
56  
57  
58  
59  
60



1  
2  
3 involvement to the design and results of the study. The regional ethical review board at the  
4  
5 University of Gothenburg, Sweden, approved the study.  
6  
7

8 After merging the data of SOReg and NDR, we identified individuals with diabetes and obesity  
9  
10 who had undergone GBP between January 1, 2007 and December 31, 2015. We subsequently  
11  
12 matched them with control patients in the NDR who had not undergone bariatric surgery.  
13

14 Propensity score matching (1:1) was performed on the basis of sex, age (18-75 years), body mass  
15  
16 index (BMI) ( $>27,5 \text{ kg/m}^2$ ) and calendar time.  
17  
18

19 We based our definition of T2DM on classical epidemiological criteria, i.e., treatment with diet,  
20  
21 oral antihyperglycemic agents, insulin or different combinations, as well patients who were  $\geq 40$   
22  
23 years of age at the time of diagnosis.  
24  
25  
26

27 All clinical characteristics at baseline were obtained from the NDR and SOReg, socioeconomic  
28  
29 status was taken from Statistics Sweden, and presurgical and postsurgical diagnoses were taken  
30  
31 from the Swedish Inpatient Register (ICD-10) (Table S1, supplementary material), which are  
32  
33 held by the National Board of Health and Welfare. The Inpatient Registry records all inpatient  
34  
35 admissions since 1987. We studied admissions to the hospitals by including specific diagnoses  
36  
37 for coronary heart disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure and  
38  
39 valvular heart disease, as well as acute and chronic diseases that were related to diabetes mellitus  
40  
41 (hyperglycemia, hypoglycemia with coma, amputation, kidney, liver and pulmonary diseases,  
42  
43 cancer, anemia, malnutrition, dementia, psychiatric disorders and alcohol abuse). We also report  
44  
45 surgical history, such as hospitalization due to bleeding, gastrointestinal (GI) surgery and  
46  
47 leakage, wound complications, GI ulcers and reflux disease, bowel obstruction, hernia, gall  
48  
49 bladder disease and pancreatitis, as well previous plastic surgery.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Patients were followed up to 9 years or until the first admission to the hospital for specific  
4 diagnoses or group of diagnoses or death. Controls who were treated with GBP were censored on  
5 the date of such treatment.  
6  
7  
8  
9

## 10 **Statistical analysis**

11  
12  
13  
14 One matched control was selected for each GBP patient using propensity scores for longitudinal  
15 exposure (22). The outcome of the propensity score matching was assessed only through  
16 descriptive statistics comparing the matched groups. Thus, controls were matched to GBP  
17 patients based on the estimated risk score from a Cox regression model with time-updated data,  
18 where exposure for GBP was the endpoint. The model contained covariates for sex, age and BMI.  
19 Controls were selected in chronological order.  
20  
21  
22  
23  
24  
25  
26  
27

28 Descriptive statistics are presented using means with standard deviation for age and BMI, median  
29 with quartiles for income and counts with percentages for all other variables. Incidence rates for  
30 each outcome were estimated using counts and person-years. Comparisons between GBP patients  
31 and controls used Cox regression, adjusted for sex, age, BMI and socioeconomic factors (income,  
32 marital status, education level and country of origin). No adjustments were made for multiple  
33 inferences. Thus, while p-values below 5% were considered statistically significant, the outcome  
34 of individual hypothesis tests should be interpreted with caution.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

## 45 **Results**

46  
47  
48 We identified 5,321 patients in the SOReg who had T2DM and had undergone GBP, as well as  
49 5,321 matched controls in the NDR (flowchart, supplementary material). Both groups were  
50 followed for up to 9 years (mean, 4.5 years). Table 1 shows the baseline characteristics of both  
51 groups. There were some minor differences between the groups (standardized differences of more  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 than 0.1): the GBP persons had a slightly higher mean age and BMI and were less likely to be  
4 single (marital status), with a greater mean income and higher educational level. The groups were  
5 well matched with respect to previous cardiovascular, gastrointestinal, psychiatric and surgical  
6 diseases (standardized differences less than 0.1).  
7  
8  
9  
10

11  
12  
13 Table 2 shows the number of events and incidence rates during the follow-up period. Event rates  
14 for all-cause mortality were 72.9 and 142.1 per 10.000 person-years in GBP and the control  
15 group respectively (HR 0.51, 95% CI 0.43-0.62; Figure 1A). Risks for cardiovascular or coronary  
16 heart disease, acute myocardial infarction and congestive heart failure (Figure 1B) were also  
17 lower after GBP.  
18  
19  
20  
21  
22  
23  
24

25 Other benefits were observed after GBP. Hospitalization for hyperglycemia was less frequent,  
26 and the risks of kidney disease (Figure 1C), leg amputation and cancer were lower (Table 2). The  
27 risks of hospitalization due to psychiatric disorders or alcohol abuse (Figure 1E-F) increased after  
28 GBP (73.1 and 26.5 per 10.000 person-years in GBP and the control group respectively, HR 1.33,  
29 95% CI 1.13-1.58 and HR 2.90, 95% CI 2.16-3.88).  
30  
31  
32  
33  
34  
35  
36

37 A number of adverse conditions were observed more often in the GBP group: abdominal pain,  
38 gallstones, gallbladder disease, pancreatitis, gastrointestinal ulcers, reflux, hernia, bowel  
39 obstruction, gastrointestinal leakage, wound complications and bleeding (Figure 2B-E).  
40  
41  
42  
43

44 Gastrointestinal or plastic surgery (Figure 2A and 2F) was required more frequently, while the  
45 risk for pulmonary complications, embolism, deep vein thrombosis or liver disease was slightly  
46 lower. GBP individuals were also at greater risk for anemia (HR 1.92, 95% CI 1.33-2.76) and  
47 malnutrition (HR 2.81, 95% CI 1.98-3.97) (Figure 1D).  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 We analyzed results of GBP treatment in men and women using a Cox regression model adjusted  
4 for sex, age, BMI and socioeconomic factors (Table S2, supplementary material). The significant  
5 interactions we noted were risks for fatal CVD, atrial fibrillation, congestive heart failure and  
6 gastrointestinal surgery (higher in men after GBP,  $p < 0.05$ ), while women were at a higher risk  
7 (1.51, 95%CI 1.23-1.85) of being hospitalized due to a psychiatric disorder after GBP.  
8  
9  
10  
11  
12  
13

## 14 15 **Discussion**

16  
17  
18 This observational study compares outcomes after GBP (rehospitalizations) in individuals with  
19 obesity and T2DM with a matched group of those who have not been surgically treated. We  
20 confirm the previously shown beneficial effects on all-cause mortality and cardiovascular  
21 morbidity in individuals with or without T2DM (1, 4), as well as presenting a panorama of short-  
22 term and long-term complications after GBP on a nationwide scale. Common reasons for  
23 postoperative hospital admissions were gastrointestinal conditions such as abdominal pain,  
24 gallstone/gallbladder disease, pancreatitis, gastrointestinal ulcer, leakage, reflux, hernia, bowel  
25 obstruction, psychiatric disorders and alcohol abuse.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 Additional gastrointestinal surgery was performed in 17.6% of the GBP group, more than three  
39 times as much as in the control group. Gastrointestinal leakage, bleeding, abdominal pain and  
40 bowel obstruction are likely causes for these surgical interventions, as well as gallstone disease  
41 and cholecystitis, which are frequently observed after GBP and rapid weight loss (3, 23-25).  
42  
43  
44  
45  
46

47 Wanjura et al. recently showed that the incidence of cholecystectomy was substantially elevated  
48 before GBP and increased 6-36 months after surgery compared with the general population (24).  
49 Previous GBP doubled the risk of complications after cholecystectomy and almost quadrupled  
50 the risk of reoperation. It has been suggested that defective gallbladder emptying in conjunction  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 with the production of crystallization-promoting compounds (mucin) can contribute to the  
4 development of cholesterol crystals and gallstones in obese subjects during weight reduction  
5  
6  
7  
8 (25).  
9

10 Some postoperative complications were common shortly after GBP (leakage, wound  
11 complications and ulcer/reflux), while others (hernia, bowel obstruction and gallstone) generally  
12 increased after 1-2 years. These findings were expected, although the incidence of ulcers and  
13 reflux disease soon after GBP may be exaggerated due to the endoscopies for dyspepsia and  
14 dysphoric symptoms. Hernias may well be undiagnosed preoperatively but detected during  
15 surgery and become symptomatic after weight loss when the associated fat disappears. The  
16 incidence of wound complications and gastrointestinal leakage shortly after GBP was comparable  
17 to other studies with short follow-up periods and a small percentage of patients with diabetes (26-  
18 28). There were no major differences between men and women in the risk for specific  
19 postoperative complications, apart from a slightly higher incidence of additional surgical  
20 procedures and cardiovascular risk (fatal CVD) in men, as previously suggested (12, 29).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 There was a 42% lower relative risk of hospitalization due to severe kidney disease after GBP. A  
37 systematic review has previously suggested that weight loss is associated with reductions in  
38 proteinuria and microalbuminuria. A retrospective cohort study showed a higher mean estimated  
39 glomerular filtration rate (eGFR) in patients up to three years after bariatric surgery than those  
40 with moderately impaired renal function (CKD stages 3 and 4) who were referred for, but did not  
41 receive, surgery (30, 31). There has been no prospective study in patients with severe renal  
42 disease. Retrospective data are limited by study design and estimations of renal function. eGFR  
43 calculations depend on muscle mass and serum creatinine levels, both of which change after  
44 weight loss independent of kidney function. Although the selection of patients eligible for  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 bariatric surgery can contribute to the apparent beneficial effects on risk of severe kidney disease,  
4 these results should prompt new studies concerning the effects on renal function, as well as  
5  
6 optimal patients for surgery to treat weight loss. Improved glycemic and blood pressure control  
7  
8 after GBP could also contribute to the apparent effects (32, 33) including changes in dose of  
9  
10 antihypertensives, which are known to affect serum creatinine. We did not evaluate glycemic  
11  
12 control in this study, but pronounced effects after bariatric surgery have been demonstrated  
13  
14 repeatedly (7, 34, 35).  
15  
16  
17  
18

19  
20 The anatomical and physiological consequences of GBP result in a higher risk of long-term  
21  
22 deficiencies of several vitamins and minerals (36). The present study had no access to data from  
23  
24 primary care, where follow-up should start 2 years after GBP, but malnutrition and anemia were  
25  
26 twice as common. Poor compliance with vitamin and mineral supplements, as well as irregular  
27  
28 follow-up, may very likely explain these results. A recent meta-analysis pointed to this potential  
29  
30 problem in individuals without diabetes, suggesting that diabetes is not a risk factor per se (14).  
31  
32 Adequate supplementation is paramount (37), since deficiencies after GBP tend to increase over  
33  
34 time (14, 38).  
35  
36  
37  
38

39 A history of psychiatric disorders requiring hospitalization was not uncommon in either group of  
40  
41 individuals with obesity in this study, and was 33% higher after GBP. Previous studies have  
42  
43 shown that depression, which may improve in the first year following bariatric surgery, tends to  
44  
45 progress (39) along with suicide and self-harm, particularly if they are preexisting conditions (15,  
46  
47 16). Thus, greater awareness is needed in order to identify vulnerable patients with a history  
48  
49 of self-harm or depression who may need psychiatric services after GBP. In agreement with  
50  
51 previous studies (17, 40) we confirmed a higher event rate of alcohol-related problems that lead  
52  
53 to hospitalization after GBP, which points to the importance of careful selection of patients who  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 are offered surgery, as well as better follow-up of those with a history of alcohol-related risk  
4  
5 behavior. The mechanisms of this well-known phenomenon are still unknown.  
6  
7

8 A major strength of this study is its nationwide coverage of patients with obesity and type 2  
9  
10 diabetes, all of whom received recent Roux-en-Y gastric bypass surgery. The results are likely to  
11  
12 be generalizable to similar developed countries using the same criteria and contraindications for  
13  
14 bariatric surgery and quality of care. All linked databases are characterized by high participation  
15  
16 rates and validation of medical data (21, 41).  
17  
18

19  
20 Our study was nonrandomized and observational, but with carefully matched groups to maximize  
21  
22 the size of the cohort as well as to reduce the influence of confounding factors. Minor differences  
23  
24 in clinical characteristics may still influence our results. We did not exclude patients with  
25  
26 multiple comorbidities before the intervention because we would have lost substantial data and  
27  
28 they had all qualified for GBP. We also used Cox proportional hazards regression modelling,  
29  
30 including baseline characteristics, to minimize the effects of confounding. Certainly, we cannot  
31  
32 rule out residual confounding, unobserved factors that may be related to both exposure and  
33  
34 outcome. However, the external validity is most likely high as our study includes virtually all  
35  
36 GBP patients with type 2 diabetes in Sweden during the time period.  
37  
38

39  
40 Another limitation is that we captured diagnoses during hospitalization, not outpatient care.  
41  
42

43  
44 Comorbidities and incidence of postoperative outcomes may be underestimated as a result, but  
45  
46 the systemic flaw could not be avoided. Nevertheless, measurement errors may potentially arise  
47  
48 because the patients who had received surgery were followed up more frequently than the control  
49  
50 group. GBP was the only surgical procedure we studied, given that sleeve gastrectomy and  
51  
52 duodenal switch were not performed very often and follow-up data were too limited during the  
53  
54 study period.  
55  
56  
57  
58  
59  
60

1  
2  
3 Individuals with obesity and type 2 diabetes who have undergone GBP are generally at a reduced  
4 risk of all-cause mortality and cardiovascular morbidity, as well as severe kidney disease and  
5 cancer to a lesser extent. They also have, however, significantly higher risks of postoperative  
6 complications and adverse events both short-term and long-term, mostly abdominal pain and  
7 gastrointestinal conditions that frequently require additional surgical procedures, apart from  
8 reconstructive plastic surgery. Long-term consequences observed more often are anemia,  
9 malnutrition, psychiatric disorders and alcohol abuse. In order to maximize the benefit and  
10 minimize the risk of problems, long-term postoperative monitoring and support should be  
11 provided. Better selection of patients for such treatment, performed by appropriate specialists in  
12 interdisciplinary settings, could probably also optimize outcomes.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35  
36 **Author Contributions:** All authors contributed to the conception and design of the study. SF,  
37 MM, AMS, JO and IN contributed to the acquisition of data and SF performed the statistical  
38 analyses. All authors contributed to the interpretation of data. VL and BE drafted the article, and  
39 all authors contributed to critical revision. BE is the guarantor of this work, had full access to the  
40 data and assumes responsibility for their integrity and analysis.  
41  
42  
43  
44  
45  
46  
47

48 **Competing of interest:** All authors have completed the ICMJE uniform disclosure form at  
49 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for the  
50 submitted work; no financial relationships with any organisations that might have an interest in  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 the submitted work in the previous three years; no other relationships or activities that could  
4  
5 appear to have influenced the submitted work.  
6  
7

8 **Funding:** The Swedish Association of Local Authorities and Regions funds the National  
9  
10 Diabetes Register and the Scandinavian Obesity Surgery Register. Region Västra Götaland also  
11  
12 provides funding for the NDR.  
13  
14  
15

16 **Data sharing statement:** This is a registry study and therefore the data generated is not suitable  
17  
18 for sharing beyond that contained within the report. Further information can be obtained from the  
19  
20 corresponding author.  
21  
22

23 **Ethical Approval:** Ethics Review Board of the University of Gothenburg approved this study.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

## 39 **References**

- 41 1. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric  
42 surgery on mortality in Swedish obese subjects. *The New England journal of medicine*. 2007;357(8):741-  
43 52.  
44
- 45 2. Kwok CS, Pradhan A, Khan MA, Anderson SG, Keavney BD, Myint PK, et al. Bariatric surgery  
46 and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis.  
47 *International journal of cardiology*. 2014;173(1):20-8.
- 48 3. Melmer A, Sturm W, Kuhnert B, Engl-Prosch J, Ress C, Tschoner A, et al. Incidence of Gallstone  
49 Formation and Cholecystectomy 10 Years After Bariatric Surgery. *Obesity surgery*. 2015;25(7):1171-6.
- 50 4. Eliasson B, Liakopoulos V, Franzen S, Naslund I, Svensson AM, Ottosson J, et al. Cardiovascular  
51 disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide,  
52 matched, observational cohort study. *The lancet Diabetes & endocrinology*. 2015;3(11):847-54.
- 53 5. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2  
54 diabetes after bariatric surgery: systematic review and meta-analysis. *The American journal of medicine*.  
55 2009;122(3):248-56. e5.  
56  
57  
58  
59  
60

6. Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. *Jama*. 2014;311(22):2297-304.
7. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. *The New England journal of medicine*. 2017;376(7):641-51.
8. Cummings DE, Arterburn DE, Westbrook EO, Kuzma JN, Stewart SD, Chan CP, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. *Diabetologia*. 2016;59(5):945-53.
9. Ikramuddin S, Billington CJ, Lee WJ, Bantle JP, Thomas AJ, Connett JE, et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. *The lancet Diabetes & endocrinology*. 2015;3(6):413-22.
10. Saunders JK, Ballantyne GH, Belsley S, Stephens D, Trivedi A, Ewing DR, et al. 30-day readmission rates at a high volume bariatric surgery center: laparoscopic adjustable gastric banding, laparoscopic gastric bypass, and vertical banded gastroplasty-Roux-en-Y gastric bypass. *Obesity surgery*. 2007;17(9):1171-7.
11. Berger ER, Huffman KM, Fraker T, Petrick AT, Brethauer SA, Hall BL, et al. Prevalence and Risk Factors for Bariatric Surgery Readmissions: Findings From 130,007 Admissions in the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program. *Ann Surg*. 2016.
12. Dayer-Jankechova A, Fournier P, Allemann P, Suter M. Complications After Laparoscopic Roux-en-Y Gastric Bypass in 1573 Consecutive Patients: Are There Predictors? *Obesity surgery*. 2016;26(1):12-20.
13. Bruze G, Ottosson J, Neovius M, Naslund I, Marsk R. Hospital admission after gastric bypass: a nationwide cohort study with up to 6 years follow-up. *Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery*. 2017;13(6):962-9.
14. Weng TC, Chang CH, Dong YH, Chang YC, Chuang LM. Anaemia and related nutrient deficiencies after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis. *BMJ open*. 2015;5(7):e006964.
15. Lagerros YT, Brandt L, Hedberg J, Sundbom M, Boden R. Suicide, Self-harm, and Depression After Gastric Bypass Surgery: A Nationwide Cohort Study. *Ann Surg*. 2017;265(2):235-43.
16. Neovius M, Bruze G, Jacobson P, Sjöholm K, Johansson K, Granath F, et al. Risk of suicide and non-fatal self-harm after bariatric surgery: results from two matched cohort studies. *The lancet Diabetes & endocrinology*. 2018.
17. Svensson PA, Anveden A, Romeo S, Peltonen M, Ahlin S, Burza MA, et al. Alcohol consumption and alcohol problems after bariatric surgery in the Swedish obese subjects study. *Obesity (Silver Spring, Md)*. 2013;21(12):2444-51.
18. Ikramuddin S, Korner J, Lee WJ, Thomas AJ, Connett JE, Bantle JP, et al. Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study. *Jama*. 2018;319(3):266-78.
19. Shin JH, Worni M, Castleberry AW, Pietrobon R, Omotosho PA, Silberberg M, et al. The application of comorbidity indices to predict early postoperative outcomes after laparoscopic Roux-en-Y gastric bypass: a nationwide comparative analysis of over 70,000 cases. *Obesity surgery*. 2013;23(5):638-49.
20. Eliasson B, Gudbjornsdottir S. Diabetes care--improvement through measurement. *Diabetes research and clinical practice*. 2014;106 Suppl 2:S291-4.
21. Hedenbro JL, Naslund E, Boman L, Lundegardh G, Bylund A, Ekelund M, et al. Formation of the Scandinavian Obesity Surgery Registry, SOReg. *Obesity surgery*. 2015;25(10):1893-900.
22. Lu B. Propensity score matching with time-dependent covariates. *Biometrics*. 2005;61(3):721-8.

23. Gustafsson U, Benthin L, Granstrom L, Groen AK, Sahlin S, Einarsson C. Changes in gallbladder bile composition and crystal detection time in morbidly obese subjects after bariatric surgery. *Hepatology* (Baltimore, Md). 2005;41(6):1322-8.
24. Wanjura V, Sandblom G, Osterberg J, Enochsson L, Ottosson J, Szabo E. Cholecystectomy after gastric bypass-incidence and complications. *Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery*. 2017;13(6):979-87.
25. Wanjura V, Szabo E, Osterberg J, Ottosson J, Enochsson L, Sandblom G. Morbidity of cholecystectomy and gastric bypass in a national database. *The British journal of surgery*. 2017.
26. Stenberg E, Szabo E, Agren G, Naslund E, Boman L, Bylund A, et al. Early complications after laparoscopic gastric bypass surgery: results from the Scandinavian Obesity Surgery Registry. *Ann Surg*. 2014;260(6):1040-7.
27. Maciejewski ML, Winegar DA, Farley JF, Wolfe BM, DeMaria EJ. Risk stratification of serious adverse events after gastric bypass in the Bariatric Outcomes Longitudinal Database. *Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery*. 2012;8(6):671-7.
28. Yong PH, Weinberg L, Torkamani N, Churilov L, Robbins RJ, Ma R, et al. The Presence of Diabetes and Higher HbA1c Are Independently Associated With Adverse Outcomes After Surgery. *Diabetes Care*. 2018.
29. Livingston EH, Huerta S, Arthur D, Lee S, De Shields S, Heber D. Male gender is a predictor of morbidity and age a predictor of mortality for patients undergoing gastric bypass surgery. *Ann Surg*. 2002;236(5):576-82.
30. Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2010;25(4):1173-83.
31. Imam TH, Fischer H, Jing B, Burchette R, Henry S, DeRose SF, et al. Estimated GFR Before and After Bariatric Surgery in CKD. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2017;69(3):380-8.
32. Sjöström L, Lindroos A-K, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *New England Journal of Medicine*. 2004;351(26):2683-93.
33. Courcoulas AP, King WC, Belle SH, Berk P, Flum DR, Garcia L, et al. Seven-Year Weight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study. *JAMA surgery*. 2017.
34. Liakopoulos V, Franzén S, Svensson A-M, Zethelius B, Ottosson J, Näslund I, et al. Changes in risk factors and their contribution to reduction of mortality risk following gastric bypass surgery among obese individuals with type 2 diabetes: a nationwide, matched, observational cohort study. *BMJ Open Diabetes Research & Care*. 2017;5(1).
35. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. *Lancet (London, England)*. 2015;386(9997):964-73.
36. Shah M, Simha V, Garg A. Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. *The Journal of clinical endocrinology and metabolism*. 2006;91(11):4223-31.
37. Ziegler O, Sirveaux MA, Brunaud L, Reibel N, Quilliot D. Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies. *Diabetes & metabolism*. 2009;35(6 Pt 2):544-57.
38. Olbers T, Beamish AJ, Gronowitz E, Flodmark CE, Dahlgren J, Bruze G, et al. Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study. *The lancet Diabetes & endocrinology*. 2017;5(3):174-83.

- 1  
2  
3 39. Mitchell JE, King WC, Chen JY, Devlin MJ, Flum D, Garcia L, et al. Course of depressive  
4 symptoms and treatment in the longitudinal assessment of bariatric surgery (LABS-2) study. *Obesity*  
5 (Silver Spring, Md). 2014;22(8):1799-806.  
6 40. King WC, Chen JY, Mitchell JE, Kalarchian MA, Steffen KJ, Engel SG, et al. Prevalence of  
7 alcohol use disorders before and after bariatric surgery. *Jama*. 2012;307(23):2516-25.  
8 41. Emilsson L, Lindahl B, Koster M, Lambe M, Ludvigsson JF. Review of 103 Swedish Healthcare  
9 Quality Registries. *Journal of internal medicine*. 2015;277(1):94-136.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20  
21 **Figure legends:**

22  
23 **Figure 1A-F:** Cumulative incidence of postoperative outcomes during the 9-years follow up. All-  
24 cause mortality; Congestive heart failure; Kidney disease; Malnutrition; Psychiatric disorder;  
25 Alcohol abuse.  
26

27  
28  
29 **Figure 2A-F:** Cumulative incidence of postoperative adverse events during the 9-years follow-  
30 up. Gastrointestinal (GI) surgery; Abdominal pain; Bowel obstruction; Gallstone and gallbladder  
31 disease; Wound complications; Plastic surgery  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

<b>Table 1. Baseline characteristics</b>			
	<b>BMJ Open</b>		
	<b>GBP (n=5321)</b>	<b>Control (n=5321)</b>	<b>Standardized difference*</b>
Sex			
Men	2098 (39.4%)	1926 (36.2%)	0.0471
Women	3223 (60.5%)	3395 (63.8%)	0.0471
Age	49.0 (9.5)	47.1 (11.5)	0.122
BMI	42.0 (5.7)	40.9 (7.3)	0.117
Income (SEK)	199.638 (139136; 261558)	168.380 (121840; 239368)	0.156
Marital status			
Single	1602 (30.1%)	2064 (38.8%)	0.130
Married	2518 (47.4%)	2227 (41.9%)	0.0781
Separated	1092 (20.5%)	881 (16.6%)	0.0723
Widowed	106 (2.0%)	147 (2.8%)	0.0358
Education level			
Compulsory school	1069 (20.1%)	1431 (26.9%)	0.114
University	3192 (60.0%)	2847 (53.5%)	0.0926
Upper secondary school	1037 (19.5%)	930 (17.5%)	0.0366
Missing data	23 (0.4%)	113 (2.1%)	0.107
Country of origin			
Sweden	4261 (80.1%)	4027 (75.7%)	0.075
Rest of Europe	514 (9.7%)	602 (11.3%)	0.0382
Rest of the world	546 (10.3%)	692 (13.0%)	0.0607
Cardiovascular			
Cardiovascular disease	273 (5.1%)	261 (4.9%)	0.00730
Acute myocardial infarction	173 (3.2%)	169 (3.2%)	0.00301
Coronary heart disease	395 (7.4%)	313 (5.9%)	0.0437
Congestive heart failure	140 (2.6%)	168 (3.2%)	0.0222
Atrial fibrillation	148 (2.8%)	149 (2.8%)	0.000807
Valvular heart disease	24 (0.4%)	27 (0.5%)	0.00577
Stroke	109 (2.0%)	103 (1.9%)	0.00571
Deep vein thrombosis/pulmonary embolism	71 (1.3%)	65 (1.2%)	0.00710
Diabetes-related			
Hyperglycemia	80 (1.5%)	130 (2.4%)	0.0478
Hypoglycemia (with or without coma)	57 (1.1%)	61 (1.2%)	0.00508

Numbers and proportions.

\*Difference between sample means divided by standard deviation. Acceptable significance when standardized difference <0.1

Gastrointestinal			
Gastrointestinal surgery (not gastric bypass)	549 (10.3%)	644 (12.1%)	0.0400
Abdominal pain	386 (7.2%)	334 (6.3%)	0.0275
Gallstone, gallbladder disease and pancreatitis	419 (7.9%)	366 (6.9%)	0.0270
Gastrointestinal ulcer and reflux	86 (1.6%)	72 (1.4%)	0.0154
Hernia	204 (3.8%)	160 (3.0%)	0.0322
Bowel obstruction	18 (0.3%)	29 (0.6%)	0.0220
Gastrointestinal leakage	7 (0.1%)	17 (0.3%)	0.0280
Liver disease	16 (0.3%)	26 (0.5%)	0.0212
Surgical			
Plastic surgery	54 (1.0%)	33 (0.6%)	0.0310
Wound complications	192 (3.6%)	156 (2.9%)	0.0269
Bleeding	50 (0.9%)	32 (0.6%)	0.0273
Other			
Psychiatric disorders	318 (6.0%)	346 (6.5%)	0.0154
Alcohol abuse	94 (1.8%)	122 (2.3%)	0.0264
Cancer	111 (2.1%)	158 (3.0%)	0.0398
Malnutrition	21 (0.4%)	41 (0.8%)	0.0349
Kidney disease	56 (1.0%)	83 (1.6%)	0.0316
Pulmonary disease	128 (2.4%)	131 (2.5%)	0.00259
Anemia	55 (1.0%)	60 (1.1%)	0.00643
Amputation	10 (0.2%)	12 (0.2%)	0.00585
Dementia	1 (0.02%)	4 (0.08%)	0.0184

**Table 2. Number of events and event rates during follow up**

Outcome	GBP (n=5321)	Control (n=5321)	Hazard ratio [95% CI]	p-value
All-cause mortality	183 (72.90)	351 (142.06)	0.51 [0.43, 0.62]	<.0001
Cardiovascular				
Cardiovascular disease	108 (43.54)	150 (61.54)	0.66 [0.51, 0.85]	0.0014
Fatal cardiovascular disease	21 (8.38)	64 (25.94)	0.34 [0.20, 0.56]	<.0001
Acute myocardial infarction	51 (20.43)	85 (34.69)	0.55 [0.39, 0.79]	0.0010

**Table 2. Number of events and event rates during follow up**

<b>Outcome</b>	<b>GBP (n=5321)</b>	<b>Control (n=5321)</b>	<b>Hazard ratio [95% CI]</b>	<b>p-value</b>
Coronary heart disease	309 (128.66)	274 (114.28)	1.13 [0.95, 1.34]	0.156
Fatal coronary heart disease	28 (11.17)	77 (31.20)	0.35 [0.22, 0.54]	<.0001
Congestive heart failure	109 (43.94)	225 (93.05)	0.49 [0.39, 0.62]	<.0001
Atrial fibrillation	204 (83.64)	213 (88.16)	0.93 [0.76, 1.14]	0.486
Valvular heart disease	21 (8.39)	32 (13.00)	0.64 [0.36, 1.14]	0.131
Stroke	59 (23.69)	71 (28.94)	0.77 [0.54, 1.10]	0.158
Deep vein thrombosis/pulmonary embolism	56 (22.48)	59 (24.07)	1.01 [0.69, 1.48]	0.952
Diabetes-related				
Hypoglycemia (with or without coma)	43 (17.24)	46 (18.72)	1.04 [0.68, 1.60]	0.844
Hyperglycemia	23 (9.20)	89 (36.37)	0.33 [0.21, 0.53]	<.0001
Gastrointestinal				
Gastrointestinal surgery (not gastric bypass)	936 (422.59)	301 (125.76)	3.33 [2.91, 3.80]	<.0001
Abdominal pain	558 (239.25)	124 (50.94)	5.52 [4.51, 6.75]	<.0001
Gallstone, gallbladder disease and pancreatitis	312 (129.31)	125 (51.30)	2.49 [2.02, 3.08]	<.0001
Gastrointestinal ulcer and reflux	239 (98.58)	46 (18.73)	5.42 [3.91, 7.51]	<.0001
Hernia	235 (97.00)	86 (35.17)	2.75 [2.14, 3.54]	<.0001
Bowel obstruction	232 (95.29)	27 (10.97)	9.47 [6.31, 14.20]	<.0001
Gastrointestinal leakage	40 (16.05)	7 (2.84)	5.54 [2.46, 12.45]	<.0001
Liver disease	30 (12.00)	40 (16.26)	0.73 [0.45, 1.19]	0.205
Surgical				
Plastic surgery	380 (158.08)	22 (8.94)	19.85 [12.86, 30.67]	<.0001
Wound complications	290 (120.87)	87 (35.55)	3.45 [2.70, 4.42]	<.0001
Bleeding	172 (70.50)	26 (10.57)	6.87 [4.49, 10.52]	<.0001
Other				
Psychiatric disorder	317 (131.64)	268 (111.93)	1.33 [1.13, 1.58]	0.0008
Alcohol abuse	180 (73.10)	65 (26.52)	2.90 [2.16, 3.88]	<.0001
Cancer	153 (61.80)	188 (77.41)	0.78 [0.63, 0.97]	0.0257
Malnutrition	128 (51.69)	46 (18.72)	2.81 [1.98, 3.97]	<.0001
Kidney disease	105 (42.38)	187 (76.87)	0.58 [0.45, 0.75]	<.0001
Pulmonary complications	86 (34.66)	114 (46.64)	0.84 [0.63, 1.13]	0.249



**Table 2. Number of events and event rates during follow up**

<b>Outcome</b>	<b>GBP (n=5321)</b>	<b>Control (n=5321)</b>	<b>Hazard ratio [95% CI]</b>	<b>p-value</b>
Anemia	84 (33.78)	46 (18.71)	1.92 [1.33, 2.76]	0.0005
Amputation	15 (5.99)	23 (9.33)	0.51 [0.26, 0.98]	0.0432
Dementia	4 (1.60)	12 (4.87)	0.46 [0.14, 1.57]	0.214

Event rates (%) per 10.000 person-years

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1A-F: Cumulative incidence of postoperative outcomes during the 9-years follow up. All-cause mortality; Congestive heart failure; Kidney disease; Malnutrition; Psychiatric disorder; Alcohol abuse.




Figure 2A-F: Cumulative incidence of postoperative adverse events during the 9-years follow-up. Gastrointestinal (GI) surgery; Abdominal pain; Bowel obstruction; Gallstone and gallbladder disease; Wound complications; Plastic surgery


## SUPPLEMENTARY MATERIAL

### Table of contents

- Flowchart – patient selection
- Methods – database linkages
- Table S1. ICD-10 codes
- Table S2. Risk estimates for men and women

### Flowchart

Selection of our data from Scandinavian Obesity Surgery Register (SOReg) before merging with data from the National Diabetes Registry (NDR).



Merging the two databases led to our study population of 5,321 patients in the SOReg who had T2DM and had undergone GBP, and 5,321 matched control patients in the NDR.

### Methods – database linkages

This study is based on data from the NDR and SOReg. Both registers are linked to Statistics Sweden at the National Board of Health and Welfare, which also stores data in the Swedish Inpatient Register (1997-2015).

We filed an application with our data and personal identity numbers [SOReg (2007-2013) & NDR (1996-2015)] to the National Board of Health and Welfare, from which all personal identity numbers have been identified and replaced by serial numbers. The coded data from the National Board of Health and Welfare were subsequently forwarded to Statistics Sweden for linkage with the Inpatient Register and LISA Database, which provides socioeconomic data. The linked data were then returned to us for validation and analysis.

**Table S1: Pre-index diagnoses and outcomes after GBP**

Diagnoses before and after gastric bypass surgery (index date) until December 2015 according to ICD-10.

Diagnosis	ICD-10	Variable origin	Registration period
Acute Myocardial infarction	<i>I21</i>	Swedish Inpatient Register	2007-2015
Coronary heart disease	<i>I20-25</i>	Swedish Inpatient Register	2007-2015
Stroke	<i>I61-64</i>	Swedish Inpatient Register	2007-2015
Cardiovascular disease	<i>I21, I61-64</i>	Swedish Inpatient Register	2007-2015
Atrial fibrillation	<i>I48</i>	Swedish Inpatient Register	2007-2015
Heart failure	<i>I50</i>	Swedish Inpatient Register	2007-2015
Valvular heart disease	<i>I05-09, I34-37, Q22, Q23</i>	Swedish Inpatient Register	2007-2015
Liver disease	<i>K70-74</i>	Swedish Inpatient Register	2007-2015
Kidney disease	<i>V42A, V45B, V56A, V56W, Z940, Z491, Z492, Z992, N17-19, N99</i>	Swedish Inpatient Register	2007-2015
Hyperglycemia	<i>E100, E101, E110, E111, E120, E121, E130, E131, E140, E141, R739</i>	Swedish Inpatient Register	2007-2015
Hypoglycemia (with or without coma)	<i>E100, E106A, E110, E110C, E110X, E116A, E120, E130, E140, E159, E160, E161W, E162, R402</i>	Swedish Inpatient Register	2007-2015
Cancer	<i>C0-9</i>	Swedish Inpatient Register	2007-2015

Dementia	<i>G300, G301, G308, G309, G31, F00-03</i>	Swedish Inpatient Register	2007-2015
Psychiatric disorders	<i>F11-19, F20-29, F30-39, F50, F55, F40-F43, F60, F61, F68, F69, F99</i>	Swedish Inpatient Register	2007-2015
Alcohol abuse	<i>F10</i>	Swedish Inpatient Register	2007-2015
Anemia	<i>D508-9, D51.0,3,8, D520</i>	Swedish Inpatient Register	2007-2015
Malnutrition	<i>E15-16, E51.2, E42-44, E46, E50-64, G63.3-4, G62.9, K91.1-2, M81.3, M83.2</i>	Swedish Inpatient Register	2007-2015
Bleeding	<i>T81.0</i>	Swedish Inpatient Register	2007-2015
Deep vein thrombosis and pulmonary embolism	<i>I80.0-9, I26, I81</i>	Swedish Inpatient Register	2007-2015
Amputation	<i>NHQ09, 11-14, 16, 17, 99, NGQ09, 19, 99, NFQ19, 99</i>	Swedish Inpatient Register	2007-2015
Bowel obstruction	<i>K56, K45</i>	Swedish Inpatient Register	2007-2015
Gastrointestinal leakage	<i>T84.4, K65.0, K63.1</i>	Swedish Inpatient Register	2007-2015
Pulmonary complications	<i>J18.0-9, J69.0, J80, J98.1</i>	Swedish Inpatient Register	2007-2015
Wound complications	<i>T81.3-4, K43.0-9</i>	Swedish Inpatient Register	2007-2015
Gastrointestinal ulcer and reflux	<i>K21, K22.1-3, K25-26, K28</i>	Swedish Inpatient Register	2007-2015
Hernia	<i>K40-43</i>	Swedish Inpatient Register	2007-2015
Gallstone, gallbladder disease and pancreatitis	<i>K80-85</i>	Swedish Inpatient Register	2007-2015
Gastrointestinal surgery not	All the operative diagnoses with	Swedish Inpatient Register	2007-2015



1	GBP	"J" except for gastric operation	Register	
2				
3	Plastic surgery	<i>QBE, QBJ, QCJ05, QDJ05, QAJ35</i>	Swedish Inpatient Register	2007-2015
4				
5	Abdominal pain	<i>R10.1-4</i>	Swedish Inpatient Register	2007-2015
6				
7	All-cause mortality	Everyone in the Cause of Death Register	Cause of Death Register	2007-2015
8				
9	Fatal coronary heart disease	<i>I20-24</i> and entered in the Cause of Death Register	Swedish Inpatient Register & Cause of Death Register	2007-2015
10				
11	Fatal cardiovascular disease	<i>I20-24, I61-64</i> and entered in the Cause of Death Register	Swedish Inpatient Register & Cause of Death Register	2007-2015
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

**Table S2: Risk estimates for men and women (Cox proportional hazards regression)**

<b>Outcome</b>	<b>Men HR with 95% CI (n=4024)</b>	<b>Women HR with 95% CI (n=6618)</b>	<b>p-value</b>
All-cause mortality	0.58 (0.45, 0.74)	0.46 (0.35, 0.60)	0.2091
Coronary heart disease	1.14 (0.90, 1.44)	1.12 (0.88, 1.42)	0.9011
Cardiovascular disease	0.63 (0.44, 0.92)	0.69 (0.49, 0.96)	0.7614
Fatal coronary heart disease	0.42 (0.24, 0.73)	0.25 (0.12, 0.54)	0.2853
Fatal cardiovascular disease	0.60 (0.32, 1.14)	0.13 (0.05, 0.36)	0.0118
Acute myocardial infarction	0.55 (0.32, 0.92)	0.56 (0.35, 0.90)	0.9522
Stroke	0.67 (0.32, 1.12)	0.88 (0.55, 1.41)	0.4429
Atrial fibrillation	1.13 (0.86, 1.47)	0.72 (0.53, 0.98)	0.0313
Heart failure	0.63 (0.46, 0.86)	0.35 (0.24, 0.51)	0.0201
Valvular heart disease	0.83 (0.38, 1.84)	0.49 (0.21, 1.13)	0.3645
Hyperglycemia	0.22 (0.09, 0.53)	0.40 (0.23, 0.69)	0.2624
Hypoglycemia with coma	0.79 (0.39, 1.63)	1.21 (0.71, 2.05)	0.3490
Dementia	0.73 (0.19, 2.86)	0.00 (.,.)	0.9991
Kidney disease	0.84 (0.28, 2.54)	0.37 (0.12, 1.13)	0.2995
Amputation	0.82 (0.36, 1.85)	0.16 (0.04, 0.72)	0.0613
Cancer	1.02 (0.69, 1.51)	0.69 (0.53, 0.90)	0.1068
Psychiatric disorder	1.02 (0.76, 1.37)	1.51 (1.23, 1.85)	0.0289
Alcohol abuse	2.87 (1.98, 4.15)	2.94 (1.85, 4.69)	0.9298
Liver diseases	0.53 (0.25, 1.13)	0.92 (0.49, 1.73)	0.2731
Anemia	1.96 (0.96, 4.01)	1.90 (1.24, 2.90)	0.9390

<b>Outcome</b>	<b>Men HR with 95% CI (n=4024)</b>	<b>Women HR with 95% CI (n=6618)</b>	<b>p-value</b>
Bleeding	9.74 (4.69, 20.22)	5.50 (3.26, 9.29)	0.2110
Deep vein thrombosis and pulmonary embolism	1.10 (0.59, 2.03)	0.96 (0.60, 1.55)	0.7455
Bowel obstruction	6.17 (3.33, 11.46)	12.10 (7.10, 20.64)	0.1035
Gastrointestinal leakage	5.28 (1.55, 18.01)	5.73 (1.96, 16.79)	0.9217
Malnutrition	2.72 (1.59, 4.67)	2.86 [1.83, 4.47]	0.8879
Pulmonary complications	0.96 (0.59, 1.56)	0.78 [0.54, 1.12]	0.4915
Wound complications	4.70 (2.79, 7.90)	3.12 [2.36, 4.13]	0.1743
Gastrointestinal ulcer and reflux	5.57 (3.49, 8.89)	5.28 (3.36, 8.31)	0.8719
Hernia	3.53 (2.19, 5.69)	2.47 (1.83, 3.33)	0.2136
Gallstone, gallbladder disease and pancreatitis	2.33 (1.59, 3.41)	2.56 (1.99, 3.30)	0.6810
Gastrointestinal surgery (not gastric bypass)	9.93 (8.35, 11.80)	7.13 (6.37, 7.98)	0.0015
Plastic surgery	16.96 (6.84, 42.07)	20.73 (12.67, 33.92)	0.7024
Abdominal pain	7.22 (4.64, 11.24)	5.12 (4.08, 6.41)	0.1703

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies***

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6,7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6,7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	6, suppl
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8, suppl
		(c) Explain how missing data were addressed	-
		(d) If applicable, explain how loss to follow-up was addressed	-
		(e) Describe any sensitivity analyses	-
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	suppl
		(c) Consider use of a flow diagram	suppl
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8, 19
		(b) Indicate number of participants with missing data for each variable of interest	-
		(c) Summarise follow-up time (eg, average and total amount)	8
Outcome data	15*	Report numbers of outcome events or summary measures over time	8,9,19,21
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9,21
		(b) Report category boundaries when continuous variables were categorized	9,21
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	suppl
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10,11,12,13,14
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Pros and cons of gastric bypass surgery in obese individuals with type 2 diabetes: nationwide, matched, observational cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023882.R1
Article Type:	Research
Date Submitted by the Author:	15-Aug-2018
Complete List of Authors:	Liakopoulos, Vasileios; Goteborgs Universitet, Department of Molecular and Clinical Medicine; Sahlgrenska universitetssjukhuset, Department of Medical Clinic Franzén, Stefan; Centre of Registers Västra Götaland; Goteborgs Universitet, Health Metrics Unit, Sahlgrenska Academy Svensson, Ann-Marie; Centre of Registers in Region Västra Götaland; Goteborgs Universitet, Department of Molecular and Clinical Medicine Miftaraj, Mervete; Center of Registers in Region Västra Götaland Ottosson, Johan ; Orebro Universitet, Department of Surgery, Faculty of Medicine and Health Näslund, Ingmar; Orebro Universitet, Department of Surgery, Faculty of Medicine and Health Gudbjornsdottir, Soffia; Goteborgs Universitet; National Diabetes Register, Centre of Registers Eliasson, Björn; University of Gothenburg, Department of Medical Clinic; Goteborgs Universitet, Department of Molecular and Clinical Medicine
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Surgery
Keywords:	DIABETES & ENDOCRINOLOGY, SURGERY, Adverse events < THERAPEUTICS

SCHOLARONE™  
Manuscripts

**TITLE PAGE**

**Complete title:** Pros and cons of gastric bypass surgery in obese individuals with type 2 diabetes: nationwide, matched, observational cohort study

**Authors:**

Vasileios Liakopoulos MSc <sup>1,2</sup>

Stefan Franzén PhD <sup>3,4</sup>

Ann-Marie Svensson PhD <sup>1,3</sup>

Mervete Miftaraj MSc <sup>3</sup>

Johan Ottosson, Associate professor, PhD

Ingmar Näslund, Associate professor, PhD

Soffia Gudbjörnsdottir, Professor, PhD <sup>1,3</sup>

Björn Eliasson, Professor, PhD <sup>1,2</sup>

**Affiliations:**

1 Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden

2 Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

3 National Diabetes Register, Centre of Registers, Gothenburg, Sweden

4 Health Metrics Unit, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

5 Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

**Corresponding author:** Vasileios Liakopoulos, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

Address SE- 413 45, Gothenburg, Sweden

Phone +46 76 112 81 32

1  
2  
3 E-mail vasileios.liakopoulos@vgregion.se  
4

5 **Keywords:** diabetes mellitus; obesity; bariatric surgery; postoperative complications; adverse  
6 effects  
7  
8

9 **Word count:** 2849  
10

11 **Number of tables:** 2  
12

13 **Number of figures:** 2  
14  
15

16  
17  
18  
19 **ABSTRACT** Word count: 300  
20

21  
22 **Objectives:** Long-term effects of gastric bypass (GBP) surgery have been presented in  
23 observational and randomized studies, but there are only limited data for obese persons with type  
24 2 diabetes (T2DM) regarding postoperative complications.  
25  
26  
27  
28

29  
30 **Design:** This is a nationwide observational study based on two quality registers in Sweden  
31 (National Diabetes Register (NDR) and Scandinavian Obesity Surgery Register (SOReg)) and  
32 other national databases.  
33  
34  
35  
36

37  
38 **Setting:** After merging the data, we matched individuals with T2DM who had undergone GBP  
39 with those not surgically treated for obesity on propensity score, based on sex, age, BMI and  
40 calendar time. The risks of postoperative outcomes (rehospitalizations) were assessed using Cox  
41 regression models.  
42  
43  
44  
45  
46

47 **Participants:** We identified 5,321 patients with T2DM in the SOReg and 5,321 matched controls  
48 in the NDR, aged 18-65 years, with BMI >27.5 kg/m<sup>2</sup> and followed for up to 9 years.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59



1  
2  
3 **Primary and secondary outcome measures:** We assessed risks for all-cause mortality and  
4 hospitalizations for cardiovascular disease, severe kidney disease, as well as for surgical and  
5 other medical conditions.  
6  
7  
8

9  
10 **Results:** The results agree with the previously suggested lower risks of all-cause mortality (49%)  
11 and cardiovascular disease (34%), and we also found positive effects for severe kidney disease  
12 but significantly increased risks (2 to 9-fold) of several short-term complications after GBP, such  
13 as abdominal pain and gastrointestinal conditions, frequently requiring surgical procedures, apart  
14 from reconstructive plastic surgery. Long-term, the risk of anemia was 92% higher, malnutrition  
15 developed approximately 3 times as often, psychiatric diagnoses were 33% more frequent and  
16 alcohol abuse was 3 times as great as in the control group.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 **Conclusions:** This nationwide study confirms the benefits and describes the panorama of adverse  
28 events after bariatric surgery in obese persons with T2DM. Long-term postoperative monitoring  
29 and support, as better selection of patients by appropriate specialists in interdisciplinary settings,  
30 should be provided to optimize the outcomes.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- The major strength of our study is the unique and nationwide character of our population with type 2 diabetes that received gastric bypass operation.
- The high data reliability as well the external validity allow the generalizing of our results to similar developed countries using the same criteria and contraindications for bariatric surgery and quality of care.
- Our nonrandomized observational study may be limited by some minor differences between the matched groups on the propensity score.
- We tried to eliminate major confounders by careful matching between the two groups as well with an adjusted Cox regression model, however we cannot exclude underlying residual confounders.
- We studied effects and postoperative events after gastric bypass in in-patients (rehospitalizations) leaving unassessed a large proportion of out-patients visiting the primary care.

## MAIN TEXT

### Introduction

The most effective method for ensuring long-term weight reduction in obese individuals as well as beneficial effects on mortality, cardiovascular disease (CVD) and CV risk factors is bariatric surgery, Roux-en-Y gastric bypass (GBP) in particular (1, 2). These effects of GBP have also been shown in patients with type 2 diabetes (T2DM) in both observational (3-5) and randomized control trials (6-8) under different follow-up periods. However, it has also been demonstrated in cohorts with a low proportion of individuals with diabetes that GBP is associated with postoperative complications and readmission rates from 0.6% to 11.3% (9-12), as well as long-term adverse outcomes such as hypoglycemia (6), anemia, nutritional deficiencies (13), gallstones (14), depression (15), suicide and non-fatal self-harm (16) and alcohol problems (17).

Only few reports have addressed the long-term incidence of complications in obese patients with T2DM who have undergone bariatric surgery. The Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently (STAMPEDE) study reported adverse events of GBP and sleeve gastrectomy compared to conventional medical therapy, but only in 142 individuals with T2DM randomized at a single center with follow-up period up to 5 years (6). Similarly, the Diabetes Surgery Study recently reported clinical effects and adverse events after GBP or lifestyle–medical management in 120 individuals after 5 years (18). Larger prospective studies such as Swedish Obese Subjects (SOS) study (1) and large American observational studies with broad samples (10, 19) have addressed postoperative outcomes and readmission rates of GBP or other types of bariatric surgery, but with only a small proportion of patients who have T2DM.

1  
2  
3 We recently conducted a nationwide observational study of individuals with T2DM who  
4  
5 underwent GBP compared with matched individuals and reported beneficial effects on overall  
6  
7 mortality and cardiovascular events (3), but we did not address short-term or long-term adverse  
8  
9 effects. The objective of this observational cohort study is therefore to identify clinical benefits as  
10  
11 well as a wide spectrum of early postoperative, as well as long-term, adverse effects of GBP for  
12  
13 up to 9 years in individuals with T2DM compared to obese individuals who have not received  
14  
15 surgical treatment.  
16  
17  
18  
19

## 20 **Research Design and Methods**

21  
22  
23 This study is based on two nationwide quality registers in Sweden: the National Diabetes  
24  
25 Register (NDR) and the Scandinavian Obesity Surgery Register (SOReg), as well as linked data  
26  
27 from the Swedish Inpatient Register, the Cause of Death Register and the Statistics Sweden. All  
28  
29 these databases have previously been described and validated (20, 21). The NDR is a quality  
30  
31 register tool that provides nearly full coverage (90% for T2DM and 95% for T1DM) of Swedes  
32  
33 with diabetes since 1996. SOReg started in 2007 as a quality and research register. Since 2010, it  
34  
35 has covered virtually all bariatric procedures in Sweden. All bariatric centers report to the register  
36  
37 (surgical complications, postoperative reports and longitudinal effects).  
38  
39  
40  
41  
42

## 43 **Patient and Public Involvement**

44  
45  
46 All individuals provided verbal informed consent before being included in the NDR and SOReg  
47  
48 databases and that data could be used for research. They did not, however, provide consent for  
49  
50 this specific study. Patients have the rights to deny being included in studies by the time of  
51  
52 register. Furthermore, data and patients' personal identity numbers identified and replaced by  
53  
54 serial numbers in the National Board of Health and Welfare, so patients had not direct  
55  
56  
57  
58  
59  
60

1  
2  
3 involvement to the design and results of the study. The regional ethical review board at the  
4  
5 University of Gothenburg, Sweden, approved the study.  
6  
7

8 After merging the data of SOReg and NDR, we identified individuals with diabetes and obesity  
9  
10 who had undergone primary GBP between January 1, 2007 and December 31, 2015 (see  
11  
12 Supplementary material). We subsequently matched them with control patients in the NDR who  
13  
14 had not undergone bariatric surgery. Propensity score matching (1:1) was performed on the basis  
15  
16 of sex, age (18-75 years), body mass index (BMI) ( $>27.5 \text{ kg/m}^2$ ) and calendar time.  
17  
18

19 We based our definition of T2DM on classical epidemiological criteria, i.e., treatment with diet,  
20  
21 oral antihyperglycemic agents, insulin or different combinations, as well as patients who were  
22  
23  $\geq 40$  years of age at the time of diagnosis.  
24  
25  
26

27 All clinical characteristics at baseline were obtained from the NDR and SOReg, socioeconomic  
28  
29 status was taken from Statistics Sweden, and presurgical and postsurgical diagnoses were taken  
30  
31 from the Swedish Inpatient Register (ICD-10) (Table S1, supplementary material), which are  
32  
33 held by the National Board of Health and Welfare. The Inpatient Registry records all inpatient  
34  
35 admissions since 1987. We studied admissions to the hospitals by including specific diagnoses  
36  
37 for coronary heart disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure and  
38  
39 valvular heart disease, as well as acute and chronic diseases that were related to diabetes mellitus  
40  
41 (hyperglycemia, hypoglycemia with coma, amputation, kidney, liver and pulmonary diseases,  
42  
43 cancer, anemia, malnutrition, dementia, psychiatric disorders and alcohol abuse). We also report  
44  
45 surgical history, such as hospitalization due to bleeding, gastrointestinal (GI) surgery and  
46  
47 leakage, wound complications, GI ulcers and reflux disease, bowel obstruction, hernia, gall  
48  
49 bladder disease and pancreatitis, as well previous plastic surgery.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Patients were followed up to 9 years or until the first admission to the hospital for specific  
4 diagnoses or group of diagnoses or death. Controls who were treated with GBP were censored on  
5 the date of such treatment.  
6  
7  
8  
9

### 10 **Statistical analysis**

11  
12  
13  
14 One matched control was selected for each GBP patient using propensity scores for longitudinal  
15 exposure (22). The outcome of the propensity score matching was assessed only through  
16 descriptive statistics comparing the matched groups. Thus, controls were matched to GBP  
17 patients based on the estimated risk score from a Cox regression model with time-updated data,  
18 where exposure for GBP was the endpoint. The model contained covariates for sex, age and BMI.  
19 Controls were selected in chronological order.  
20  
21  
22  
23  
24  
25  
26  
27

28 Descriptive statistics are presented using means with standard deviation for age and BMI, median  
29 with quartiles for income and counts with percentages for all other variables. Incidence rates for  
30 each outcome were estimated using counts and person-years. Comparisons between GBP patients  
31 and controls used Cox regression, adjusted for sex, age, BMI and socioeconomic factors (income,  
32 marital status, education level and country of origin). No adjustments were made for multiple  
33 inferences. Thus, while p-values below 5% were considered statistically significant, the outcome  
34 of individual hypothesis tests should be interpreted with caution.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

### 45 **Results**

46  
47  
48 We identified 5,321 patients in the SOReg who had T2DM and had undergone GBP (96.0%  
49 laparoscopic, 1.7% initially laparoscopic and converted to open surgery, and 2.3% primary open  
50 surgery), as well as 5,321 matched controls in the NDR (flowchart, supplementary material).  
51  
52  
53

54 Both groups were followed for up to 9 years (mean, 4.5 years). Table 1 shows the baseline  
55  
56  
57

1  
2  
3 characteristics of both groups. There were some minor differences between the groups  
4  
5 (standardized differences of more than 0.1): the GBP persons had a slightly higher mean age and  
6  
7 BMI and were less likely to be single (marital status), with a greater mean income and higher  
8  
9 educational level. The groups were well matched with respect to previous cardiovascular,  
10  
11 gastrointestinal, psychiatric and surgical diseases (standardized differences less than 0.1).  
12  
13

14  
15 Table 2 shows the number of events and incidence rates during the follow-up period. Event rates  
16  
17 for all-cause mortality were 72.9 and 142.1 per 10.000 person-years in GBP and the control  
18  
19 group respectively (HR 0.51, 95% CI 0.43-0.62; Figure 1A). Risks for cardiovascular or coronary  
20  
21 heart disease, acute myocardial infarction and congestive heart failure (Figure 1B) were also  
22  
23 lower after GBP.  
24  
25

26  
27 Other benefits were observed after GBP. Hospitalization for hyperglycemia was less frequent,  
28  
29 and the risks of kidney disease (Figure 1C), leg amputation and cancer were lower (Table 2).  
30  
31 GBP individuals were, however, at greater risk for anemia (HR 1.92, 95% CI 1.33-2.76) and  
32  
33 malnutrition (HR 2.81, 95% CI 1.98-3.97) (Figure 1D). The risks of hospitalization due to  
34  
35 psychiatric disorders or alcohol abuse (Figure 1E-F) increased after GBP (73.1 and 26.5 per  
36  
37 10.000 person-years in GBP and the control group respectively, HR 1.33, 95% CI 1.13-1.58 and  
38  
39 HR 2.90, 95% CI 2.16-3.88).  
40  
41  
42  
43

44 A number of adverse conditions, frequently necessitating additional gastrointestinal surgery, were  
45  
46 also observed more often in the GBP group: abdominal pain, bowel obstruction, gallstones,  
47  
48 gallbladder disease, pancreatitis, gastrointestinal ulcers, reflux, hernia, gastrointestinal leakage,  
49  
50 wound complications and bleeding (Figure 2A-E). Subsequent reconstructive plastic surgery  
51  
52 (Figure 2F) was also required frequently, while the risk for pulmonary complications, embolism,  
53  
54 deep vein thrombosis or liver disease was slightly lower.  
55  
56  
57  
58  
59  
60

1  
2  
3 We analyzed results of GBP treatment in men and women using a Cox regression model adjusted  
4 for sex, age, BMI and socioeconomic factors (Table S2, supplementary material). The significant  
5  
6 interactions we noted were risks for fatal CVD, atrial fibrillation, congestive heart failure and  
7  
8 gastrointestinal surgery (higher in men after GBP,  $p < 0.05$ ), while women were at a higher risk  
9  
10 (1.51, 95%CI 1.23-1.85) of being hospitalized due to a psychiatric disorder after GBP.  
11  
12  
13

## 14 15 **Discussion**

16  
17 This observational study compares outcomes after GBP (rehospitalizations) in individuals with  
18  
19 obesity and T2DM with a matched group of those who have not been surgically treated. We  
20  
21 confirm the previously shown beneficial effects on all-cause mortality and cardiovascular  
22  
23 morbidity in individuals with or without T2DM (1, 3), as well as presenting a panorama of short-  
24  
25 term and long-term complications after GBP on a nationwide scale. Common reasons for  
26  
27 postoperative hospital admissions were gastrointestinal conditions such as abdominal pain,  
28  
29 gallstone/gallbladder disease, pancreatitis, gastrointestinal ulcer, leakage, reflux, hernia, bowel  
30  
31 obstruction, psychiatric disorders and alcohol abuse.  
32  
33  
34  
35  
36

37  
38 Additional gastrointestinal surgery was performed in 17.6% of the GBP group, more than three  
39  
40 times as much as in the control group. Gastrointestinal leakage, bleeding, abdominal pain and  
41  
42 bowel obstruction are likely causes for these surgical interventions, as well as gallstone disease  
43  
44 and cholecystitis, which are frequently observed after GBP and rapid weight loss (14, 23-25).

45  
46 Wanjura et al. recently showed that the incidence of cholecystectomy was substantially elevated  
47  
48 before GBP and increased 6-36 months after surgery compared with the general population (24).  
49  
50 Previous GBP doubled the risk of complications after cholecystectomy, almost quadrupled the  
51  
52 risk of reoperation (24) and the simultaneous cholecystectomy increased the risk by increasing of  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 the operation time (25). It has been suggested that defective gallbladder emptying in conjunction  
4 with the production of crystallization-promoting compounds (mucin) can contribute to the  
5 development of cholesterol crystals and gallstones in obese subjects during weight reduction  
6  
7  
8  
9  
10 (23).

11  
12 Some postoperative complications were common shortly after GBP (leakage, wound  
13 complications and ulcer/reflux), while others (hernia, bowel obstruction and gallstone) generally  
14 increased after 1-2 years. These findings were expected, although the incidence of ulcers and  
15 reflux disease soon after GBP may be exaggerated due to the endoscopies for dyspepsia and  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

Some postoperative complications were common shortly after GBP (leakage, wound complications and ulcer/reflux), while others (hernia, bowel obstruction and gallstone) generally increased after 1-2 years. These findings were expected, although the incidence of ulcers and reflux disease soon after GBP may be exaggerated due to the endoscopies for dyspepsia and dysphoric symptoms. Hernias may well be undiagnosed preoperatively but detected during surgery and become symptomatic after weight loss when the associated fat disappears. The incidence of wound complications and gastrointestinal leakage shortly after GBP was comparable to other studies with short follow-up periods and a small percentage of patients with diabetes (26-28). There were no major differences between men and women in the risk for specific postoperative complications, apart from a slightly higher incidence of additional surgical procedures and cardiovascular risk (fatal CVD) in men, as previously suggested (11, 29).

There was a 42% lower relative risk of hospitalization due to severe kidney disease after GBP. A systematic review has previously suggested that weight loss is associated with reductions in proteinuria and microalbuminuria. A retrospective cohort study showed a higher mean estimated glomerular filtration rate (eGFR) in patients up to three years after bariatric surgery than those with moderately impaired renal function (CKD stages 3 and 4) who were referred for, but did not receive, surgery (30, 31). There has been no prospective study in patients with severe renal disease. Retrospective data are limited by study design and estimations of renal function. eGFR calculations depend on muscle mass and serum creatinine levels, both of which change after

1  
2  
3 weight loss independent of kidney function. Although the selection of patients eligible for  
4 bariatric surgery can contribute to the apparent beneficial effects on risk of severe kidney disease,  
5 these results should prompt new studies concerning the effects on renal function, as well as  
6 optimal patients for surgery to treat weight loss. Improved glycemic and blood pressure control  
7 after GBP (32, 33) could also contribute to the apparent effects of including changes in dose of  
8 antihypertensives, which are known to affect serum creatinine. We did not evaluate glycemic  
9 control in this study, but pronounced effects after bariatric surgery have been demonstrated  
10 repeatedly (6, 34, 35).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 The anatomical and physiological consequences of GBP result in a higher risk of long-term  
23 deficiencies of several vitamins and minerals (36). The present study had no access to data from  
24 primary care, where follow-up should start 2 years after GBP, but malnutrition and anemia were  
25 twice as common. Poor compliance with vitamin and mineral supplements, as well as irregular  
26 follow-up, may very likely explain these results. A recent meta-analysis pointed to this potential  
27 problem in individuals without diabetes, suggesting that diabetes is not a risk factor per se (13).  
28 Adequate supplementation is paramount (37), since deficiencies after GBP tend to increase over  
29 time (13, 38).  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 A history of psychiatric disorders requiring hospitalization was not uncommon in either group of  
42 individuals with obesity in this study, and was 33% higher after GBP. Previous studies have  
43 shown that depression, which may improve in the first year following bariatric surgery, tends to  
44 progress (39) along with suicide and self-harm, particularly if they are preexisting conditions (15,  
45 16). Thus, greater awareness is needed in order to identify vulnerable patients with a history  
46 of self-harm or depression who may need psychiatric services after GBP. Perhaps specific  
47 multidisciplinary teams should identify such patients and through treatment algorithms could  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 enhance the safety and efficacy pre and postoperatively (40). In agreement with previous studies  
4  
5 (17, 41) we confirmed a higher event rate of alcohol-related problems that lead to hospitalization  
6  
7 after GBP, which points to the importance of careful selection of patients who are offered  
8  
9 surgery, as well as better follow-up of those with a history of alcohol-related risk behavior. The  
10  
11 mechanisms of this well-known phenomenon are still unknown.  
12  
13

14  
15 The indications for surgical treatment of obesity were presented by the National Institute of  
16  
17 Health in 1991 (42) and have been repeatedly revised and expanded over the years. Severe and  
18  
19 untreated psychopathology as well as active alcohol or substance abuse, or eating disorders are  
20  
21 contraindications to bariatric surgery, although the decision to offer this treatment should always  
22  
23 be individualized based on the stability of conditions and the assessment of multidisciplinary  
24  
25 treatment teams (43). The need for more robust criteria and the possible application of scoring  
26  
27 systems or algorithms that could facilitate the assessment of patients beyond BMI has been  
28  
29 discussed (44).  
30  
31  
32  
33

34 A major strength of this study is its nationwide coverage of patients with obesity and type 2  
35  
36 diabetes, all of whom received recent Roux-en-Y gastric bypass surgery. The results are likely to  
37  
38 be generalizable to similar developed countries using the same criteria and contraindications for  
39  
40 bariatric surgery and quality of care. All linked databases are characterized by high participation  
41  
42 rates and validation of medical data (21, 45).  
43  
44  
45

46 Our study was nonrandomized and observational, but with carefully matched groups to maximize  
47  
48 the size of the cohort as well as to reduce the influence of confounding factors. Minor differences  
49  
50 in clinical characteristics may still influence our results, and we also did not include some  
51  
52 variables (e.g. duration of diabetes, HbA1c, use of antidiabetic drugs) that potentially also could  
53  
54 affect the results. Similarly, we did not exclude patients with multiple comorbidities before the  
55  
56  
57  
58

1  
2  
3 intervention, because we would have lost substantial data and they had all qualified for GBP. We  
4  
5 also used Cox proportional hazards regression modelling, including baseline characteristics, to  
6  
7 minimize the effects of confounding. Certainly, we cannot rule out residual confounding,  
8  
9 unobserved factors that may be related to both exposure and outcome. However, the external  
10  
11 validity is most likely high as our study includes virtually all GBP patients with type 2 diabetes in  
12  
13 Sweden during the time period.  
14  
15

16  
17 Another limitation is that we captured diagnoses during hospitalization, not outpatient care.  
18  
19 Comorbidities and incidence of postoperative outcomes may be underestimated as a result, but  
20  
21 the systematic flaw could not be avoided. Nevertheless, measurement errors may potentially arise  
22  
23 because the patients who had received surgery were followed up more frequently than the control  
24  
25 group. GBP was the only surgical procedure we studied (96% laparoscopic), given that sleeve  
26  
27 gastrectomy and duodenal switch were not performed very often and follow-up data were too  
28  
29 limited during the study period. We also did not address the importance of more specific surgical  
30  
31 techniques.  
32  
33  
34  
35

36  
37 Individuals with obesity and type 2 diabetes who have undergone GBP are generally at a reduced  
38  
39 risk of all-cause mortality and cardiovascular morbidity, as well as severe kidney disease and  
40  
41 cancer to a lesser extent. They also have, however, significantly higher risks of postoperative  
42  
43 complications and adverse events both short-term and long-term, mostly abdominal pain and  
44  
45 gastrointestinal conditions that frequently require additional surgical procedures, apart from  
46  
47 reconstructive plastic surgery. Long-term consequences observed more often are anemia,  
48  
49 malnutrition, psychiatric disorders and alcohol abuse. In order to maximize the benefit and  
50  
51 minimize the risk of problems, long-term postoperative monitoring and support should be  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 provided. Better selection of patients for such treatment, performed by appropriate specialists in  
4  
5 interdisciplinary settings, could probably also optimize outcomes.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 **Author Contributions:** VL, SF, AMS, MM, JO, IN, SG and BE contributed to the conception  
18 and design of the study. SF, MM, AMS, JO and IN contributed to the acquisition of data and SF  
19 performed the statistical analyses. All authors contributed to the interpretation of data. VL and  
20 BE drafted the article, and VL, SF, AMS, MM, JO, IN, SG and BE contributed to critical  
21 revision. BE is the guarantor of this work, had full access to the data and assumes responsibility  
22 for their integrity and analysis.  
23  
24  
25  
26  
27  
28  
29  
30

31 **Competing of interest:** All authors have completed the ICMJE uniform disclosure form at  
32 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for the  
33 submitted work; no financial relationships with any organisations that might have an interest in  
34 the submitted work in the previous three years; no other relationships or activities that could  
35 appear to have influenced the submitted work.  
36  
37  
38  
39  
40  
41  
42  
43

44 **Funding:** The Swedish Association of Local Authorities and Regions funds the National  
45 Diabetes Register and the Scandinavian Obesity Surgery Register. Region Västra Götaland also  
46 provides funding for the NDR.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Data sharing statement:** This is a registry study and therefore the data generated is not suitable for sharing beyond that contained within the report. Further information can be obtained from the corresponding author.

**Ethical Approval:** Ethics Review Board of the University of Gothenburg approved this study.

## References

1. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. *The New England journal of medicine*. 2007;357(8):741-52.
2. Kwok CS, Pradhan A, Khan MA, Anderson SG, Keavney BD, Myint PK, et al. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. *International journal of cardiology*. 2014;173(1):20-8.
3. Eliasson B, Liakopoulos V, Franzen S, Naslund I, Svensson AM, Ottosson J, et al. Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. *The lancet Diabetes & endocrinology*. 2015;3(11):847-54.
4. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. *The American journal of medicine*. 2009;122(3):248-56. e5.
5. Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. *Jama*. 2014;311(22):2297-304.
6. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. *The New England journal of medicine*. 2017;376(7):641-51.
7. Cummings DE, Arterburn DE, Westbrook EO, Kuzma JN, Stewart SD, Chan CP, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. *Diabetologia*. 2016;59(5):945-53.
8. Ikramuddin S, Billington CJ, Lee WJ, Bantle JP, Thomas AJ, Connett JE, et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. *The lancet Diabetes & endocrinology*. 2015;3(6):413-22.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
9. Saunders JK, Ballantyne GH, Belsley S, Stephens D, Trivedi A, Ewing DR, et al. 30-day readmission rates at a high volume bariatric surgery center: laparoscopic adjustable gastric banding, laparoscopic gastric bypass, and vertical banded gastroplasty-Roux-en-Y gastric bypass. *Obesity surgery*. 2007;17(9):1171-7.
10. Berger ER, Huffman KM, Fraker T, Petrick AT, Brethauer SA, Hall BL, et al. Prevalence and Risk Factors for Bariatric Surgery Readmissions: Findings From 130,007 Admissions in the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program. *Ann Surg*. 2018 Jan;267(1):122-31.
11. Dayer-Jankechova A, Fournier P, Allemann P, Suter M. Complications After Laparoscopic Roux-en-Y Gastric Bypass in 1573 Consecutive Patients: Are There Predictors? *Obesity surgery*. 2016;26(1):12-20.
12. Bruze G, Ottosson J, Neovius M, Naslund I, Marsk R. Hospital admission after gastric bypass: a nationwide cohort study with up to 6 years follow-up. *Surg Obes Relat Dis*. 2017;13(6):962-9.
13. Weng TC, Chang CH, Dong YH, Chang YC, Chuang LM. Anaemia and related nutrient deficiencies after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis. *BMJ open*. 2015;5(7):e006964.
14. Melmer A, Sturm W, Kuhnert B, Engl-Prosch J, Ress C, Tschoner A, et al. Incidence of Gallstone Formation and Cholecystectomy 10 Years After Bariatric Surgery. *Obesity surgery*. 2015;25(7):1171-6.
15. Lagerros YT, Brandt L, Hedberg J, Sundbom M, Boden R. Suicide, Self-harm, and Depression After Gastric Bypass Surgery: A Nationwide Cohort Study. *Ann Surg*. 2017;265(2):235-43.
16. Neovius M, Bruze G, Jacobson P, Sjöholm K, Johansson K, Granath F, et al. Risk of suicide and non-fatal self-harm after bariatric surgery: results from two matched cohort studies. *Lancet Diabetes Endocrinol*. 2018;6(3):197-207.
17. Svensson PA, Anveden A, Romeo S, Peltonen M, Ahlin S, Burza MA, et al. Alcohol consumption and alcohol problems after bariatric surgery in the Swedish obese subjects study. *Obesity (Silver Spring, Md)*. 2013;21(12):2444-51.
18. Ikramuddin S, Korner J, Lee WJ, Thomas AJ, Connett JE, Bantle JP, et al. Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study. *Jama*. 2018;319(3):266-78.
19. Shin JH, Worni M, Castleberry AW, Pietrobon R, Omotosho PA, Silberberg M, et al. The application of comorbidity indices to predict early postoperative outcomes after laparoscopic Roux-en-Y gastric bypass: a nationwide comparative analysis of over 70,000 cases. *Obesity surgery*. 2013;23(5):638-49.
20. Eliasson B, Gudbjornsdottir S. Diabetes care--improvement through measurement. *Diabetes research and clinical practice*. 2014;106 Suppl 2:S291-4.
21. Hedenbro JL, Naslund E, Boman L, Lundegardh G, Bylund A, Ekelund M, et al. Formation of the Scandinavian Obesity Surgery Registry, SOReg. *Obesity surgery*. 2015;25(10):1893-900.
22. Lu B. Propensity score matching with time-dependent covariates. *Biometrics*. 2005;61(3):721-8.
23. Gustafsson U, Benthin L, Granstrom L, Groen AK, Sahlin S, Einarsson C. Changes in gallbladder bile composition and crystal detection time in morbidly obese subjects after bariatric surgery. *Hepatology*. 2005;41(6):1322-8.
24. Wanjura V, Sandblom G, Osterberg J, Enochsson L, Ottosson J, Szabo E. Cholecystectomy after gastric bypass-incidence and complications. *Surg Obes Relat Dis*. 2017;13(6):979-87.
25. Wanjura V, Szabo E, Osterberg J, Ottosson J, Enochsson L, Sandblom G. Morbidity of cholecystectomy and gastric bypass in a national database. *Br J Surg*. 2018;105(1):121-7.
26. Stenberg E, Szabo E, Agren G, Naslund E, Boman L, Bylund A, et al. Early complications after laparoscopic gastric bypass surgery: results from the Scandinavian Obesity Surgery Registry. *Ann Surg*. 2014;260(6):1040-7.



- 1
- 2
- 3
- 4 27. Maciejewski ML, Winegar DA, Farley JF, Wolfe BM, DeMaria EJ. Risk stratification of serious
- 5 adverse events after gastric bypass in the Bariatric Outcomes Longitudinal Database. *Surg Obes Relat Dis.*
- 6 2012;8(6):671-7.
- 7 28. Yong PH, Weinberg L, Torkamani N, Churilov L, Robbins RJ, Ma R, et al. The Presence of Diabetes
- 8 and Higher HbA1c Are Independently Associated With Adverse Outcomes After Surgery. *Diabetes Care.*
- 9 2018;41(6):1172-9.
- 10 29. Livingston EH, Huerta S, Arthur D, Lee S, De Shields S, Heber D. Male gender is a predictor of
- 11 morbidity and age a predictor of mortality for patients undergoing gastric bypass surgery. *Ann Surg.*
- 12 2002;236(5):576-82.
- 13 30. Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN. Weight loss and proteinuria: systematic
- 14 review of clinical trials and comparative cohorts. *Nephrol Dial Transplant.* 2010;25(4):1173-83.
- 15 31. Imam TH, Fischer H, Jing B, Burchette R, Henry S, DeRose SF, et al. Estimated GFR Before and
- 16 After Bariatric Surgery in CKD. *American journal of kidney diseases : the official journal of the National*
- 17 *Kidney Foundation.* 2017;69(3):380-8.
- 18 32. Sjöström L, Lindroos A-K, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle,
- 19 diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *New England Journal of*
- 20 *Medicine.* 2004;351(26):2683-93.
- 21 33. Courcoulas AP, King WC, Belle SH, Berk P, Flum DR, Garcia L, et al. Seven-Year Weight
- 22 Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study.
- 23 *JAMA Surg.* 2018;153(5):427-34.
- 24 34. Liakopoulos V, Franzén S, Svensson A-M, Zethelius B, Ottosson J, Näslund I, et al. Changes in risk
- 25 factors and their contribution to reduction of mortality risk following gastric bypass surgery among
- 26 obese individuals with type 2 diabetes: a nationwide, matched, observational cohort study. *BMJ Open*
- 27 *Diabetes Research & Care.* 2017;5(1).
- 28 35. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaiconelli A, Nanni G, et al. Bariatric-metabolic
- 29 surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up
- 30 of an open-label, single-centre, randomised controlled trial. *Lancet (London, England).*
- 31 2015;386(9997):964-73.
- 32 36. Shah M, Simha V, Garg A. Review: long-term impact of bariatric surgery on body weight,
- 33 comorbidities, and nutritional status. *J Clin Endocrinol Metab.* 2006;91(11):4223-31.
- 34 37. Ziegler O, Sirveaux MA, Brunaud L, Reibel N, Quilliot D. Medical follow up after bariatric surgery:
- 35 nutritional and drug issues. General recommendations for the prevention and treatment of nutritional
- 36 deficiencies. *Diabetes Metab.* 2009;35(6 Pt 2):544-57.
- 37 38. Olbers T, Beamish AJ, Gronowitz E, Flodmark CE, Dahlgren J, Bruze G, et al. Laparoscopic Roux-
- 38 en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish
- 39 nationwide study. *The lancet Diabetes & endocrinology.* 2017;5(3):174-83.
- 40 39. Mitchell JE, King WC, Chen JY, Devlin MJ, Flum D, Garcia L, et al. Course of depressive symptoms
- 41 and treatment in the longitudinal assessment of bariatric surgery (LABS-2) study. *Obesity (Silver Spring).*
- 42 2014;22(8):1799-806.
- 43 40. Spittal MJ, Fruhbeck G. Bariatric surgery: many benefits, but emerging risks. *Lancet Diabetes*
- 44 *Endocrinol.* 2018;6(3):161-3.
- 45 41. King WC, Chen JY, Mitchell JE, Kalarchian MA, Steffen KJ, Engel SG, et al. Prevalence of alcohol
- 46 use disorders before and after bariatric surgery. *Jama.* 2012;307(23):2516-25.
- 47 42. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference
- 48 Panel. *Ann Intern Med.* 1991;115(12):956-61.
- 49 43. De Luca M, Angrisani L, Himpens J, Busetto L, Scopinaro N, Weiner R, et al. Indications for
- 50 Surgery for Obesity and Weight-Related Diseases: Position Statements from the International Federation
- 51 for the Surgery of Obesity and Metabolic Disorders (IFSO). *Obes Surg.* 2016;26(8):1659-96.
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



1  
2  
3 44. Fruhbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. *Nat Rev*  
4 *Endocrinol.* 2015;11(8):465-77.

5 45. Emilsson L, Lindahl B, Koster M, Lambe M, Ludvigsson JF. Review of 103 Swedish Healthcare  
6 Quality Registries. *J Intern Med.* 2015;277(1):94-136.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 **Figure legends:**

18  
19  
20 **Figure 1A-F:** Cumulative incidence of postoperative outcomes during the 9-years follow up. All-  
21 cause mortality; Congestive heart failure; Kidney disease; Malnutrition; Psychiatric disorder;  
22 Alcohol abuse.  
23

24  
25  
26 **Figure 2A-F:** Cumulative incidence of postoperative adverse events during the 9-years follow-  
27 up. Gastrointestinal (GI) surgery; Abdominal pain; Bowel obstruction; Gallstone and gallbladder  
28 disease; Wound complications; Plastic surgery.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

<b>Table 1. Baseline characteristics</b>			
	<b>BMJ Open</b>		
	<b>GBP (n=5321)</b>	<b>Control (n=5321)</b>	<b>Standardized difference*</b>
Sex			
Men	2098 (39.4%)	1926 (36.2%)	0.0471
Women	3223 (60.5%)	3395 (63.8%)	0.0471
Age	49.0 (9.5)	47.1 (11.5)	0.122
BMI	42.0 (5.7)	40.9 (7.3)	0.117
Income (SEK)	199.638 (139136; 261558)	168.380 (121840; 239368)	0.156
Marital status			
Single	1602 (30.1%)	2064 (38.8%)	0.130
Married	2518 (47.4%)	2227 (41.9%)	0.0781
Separated	1092 (20.5%)	881 (16.6%)	0.0723
Widowed	106 (2.0%)	147 (2.8%)	0.0358
Education level			
Compulsory school	1069 (20.1%)	1431 (26.9%)	0.114
University	3192 (60.0%)	2847 (53.5%)	0.0926
Upper secondary school	1037 (19.5%)	930 (17.5%)	0.0366
Missing data	23 (0.4%)	113 (2.1%)	0.107
Country of origin			
Sweden	4261 (80.1%)	4027 (75.7%)	0.075
Rest of Europe	514 (9.7%)	602 (11.3%)	0.0382
Rest of the world	546 (10.3%)	692 (13.0%)	0.0607
Cardiovascular			
Cardiovascular disease	273 (5.1%)	261 (4.9%)	0.00730
Acute myocardial infarction	173 (3.2%)	169 (3.2%)	0.00301
Coronary heart disease	395 (7.4%)	313 (5.9%)	0.0437
Congestive heart failure	140 (2.6%)	168 (3.2%)	0.0222
Atrial fibrillation	148 (2.8%)	149 (2.8%)	0.000807
Valvular heart disease	24 (0.4%)	27 (0.5%)	0.00577
Stroke	109 (2.0%)	103 (1.9%)	0.00571
Deep vein thrombosis/pulmonary embolism	71 (1.3%)	65 (1.2%)	0.00710
Diabetes-related			
Hyperglycemia	80 (1.5%)	130 (2.4%)	0.0478
Hypoglycemia (with or without coma)	57 (1.1%)	61 (1.2%)	0.00508

Numbers and proportions.

\*Difference between sample means divided by standard deviation. Acceptable significance when standardized difference <0.1.

Gastrointestinal			
Gastrointestinal surgery (not gastric bypass)	549 (10.3%)	644 (12.1%)	0.0400
Abdominal pain	386 (7.2%)	334 (6.3%)	0.0275
Gallstone, gallbladder disease and pancreatitis	419 (7.9%)	366 (6.9%)	0.0270
Gastrointestinal ulcer and reflux	86 (1.6%)	72 (1.4%)	0.0154
Hernia	204 (3.8%)	160 (3.0%)	0.0322
Bowel obstruction	18 (0.3%)	29 (0.6%)	0.0220
Gastrointestinal leakage	7 (0.1%)	17 (0.3%)	0.0280
Liver disease	16 (0.3%)	26 (0.5%)	0.0212
Surgical			
Plastic surgery	54 (1.0%)	33 (0.6%)	0.0310
Wound complications	192 (3.6%)	156 (2.9%)	0.0269
Bleeding	50 (0.9%)	32 (0.6%)	0.0273
Other			
Psychiatric disorders	318 (6.0%)	346 (6.5%)	0.0154
Alcohol abuse	94 (1.8%)	122 (2.3%)	0.0264
Cancer	111 (2.1%)	158 (3.0%)	0.0398
Malnutrition	21 (0.4%)	41 (0.8%)	0.0349
Kidney disease	56 (1.0%)	83 (1.6%)	0.0316
Pulmonary disease	128 (2.4%)	131 (2.5%)	0.00259
Anemia	55 (1.0%)	60 (1.1%)	0.00643
Amputation	10 (0.2%)	12 (0.2%)	0.00585
Dementia	1 (0.02%)	4 (0.08%)	0.0184

**Table 2. Number of events and event rates during follow up**

Outcome	GBP (n=5321)	Control (n=5321)	Hazard ratio [95% CI]	p-value
All-cause mortality	183 (72.90)	351 (142.06)	0.51 [0.43, 0.62]	<.0001
Cardiovascular				
Cardiovascular disease	108 (43.54)	150 (61.54)	0.66 [0.51, 0.85]	0.0014
Fatal cardiovascular disease	21 (8.38)	64 (25.94)	0.34 [0.20, 0.56]	<.0001
Acute myocardial infarction	51 (20.43)	85 (34.69)	0.55 [0.39, 0.79]	0.0010

**Table 2. Number of events and event rates during follow up**

<b>Outcome</b>	<b>GBP (n=5321)</b>	<b>Control (n=5321)</b>	<b>Hazard ratio [95% CI]</b>	<b>p-value</b>
Coronary heart disease	309 (128.66)	274 (114.28)	1.13 [0.95, 1.34]	0.156
Fatal coronary heart disease	28 (11.17)	77 (31.20)	0.35 [0.22, 0.54]	<.0001
Congestive heart failure	109 (43.94)	225 (93.05)	0.49 [0.39, 0.62]	<.0001
Atrial fibrillation	204 (83.64)	213 (88.16)	0.93 [0.76, 1.14]	0.486
Valvular heart disease	21 (8.39)	32 (13.00)	0.64 [0.36, 1.14]	0.131
Stroke	59 (23.69)	71 (28.94)	0.77 [0.54, 1.10]	0.158
Deep vein thrombosis/pulmonary embolism	56 (22.48)	59 (24.07)	1.01 [0.69, 1.48]	0.952
Diabetes-related				
Hypoglycemia (with or without coma)	43 (17.24)	46 (18.72)	1.04 [0.68, 1.60]	0.844
Hyperglycemia	23 (9.20)	89 (36.37)	0.33 [0.21, 0.53]	<.0001
Gastrointestinal				
Gastrointestinal surgery (not gastric bypass)	936 (422.59)	301 (125.76)	3.33 [2.91, 3.80]	<.0001
Abdominal pain	558 (239.25)	124 (50.94)	5.52 [4.51, 6.75]	<.0001
Gallstone, gallbladder disease and pancreatitis	312 (129.31)	125 (51.30)	2.49 [2.02, 3.08]	<.0001
Gastrointestinal ulcer and reflux	239 (98.58)	46 (18.73)	5.42 [3.91, 7.51]	<.0001
Hernia	235 (97.00)	86 (35.17)	2.75 [2.14, 3.54]	<.0001
Bowel obstruction	232 (95.29)	27 (10.97)	9.47 [6.31, 14.20]	<.0001
Gastrointestinal leakage	40 (16.05)	7 (2.84)	5.54 [2.46, 12.45]	<.0001
Liver disease	30 (12.00)	40 (16.26)	0.73 [0.45, 1.19]	0.205
Surgical				
Plastic surgery	380 (158.08)	22 (8.94)	19.85 [12.86, 30.67]	<.0001
Wound complications	290 (120.87)	87 (35.55)	3.45 [2.70, 4.42]	<.0001
Bleeding	172 (70.50)	26 (10.57)	6.87 [4.49, 10.52]	<.0001
Other				
Psychiatric disorder	317 (131.64)	268 (111.93)	1.33 [1.13, 1.58]	0.0008
Alcohol abuse	180 (73.10)	65 (26.52)	2.90 [2.16, 3.88]	<.0001
Cancer	153 (61.80)	188 (77.41)	0.78 [0.63, 0.97]	0.0257
Malnutrition	128 (51.69)	46 (18.72)	2.81 [1.98, 3.97]	<.0001
Kidney disease	105 (42.38)	187 (76.87)	0.58 [0.45, 0.75]	<.0001
Pulmonary complications	86 (34.66)	114 (46.64)	0.84 [0.63, 1.13]	0.249

**Table 2. Number of events and event rates during follow up**

<b>Outcome</b>	<b>GBP (n=5321)</b>	<b>Control (n=5321)</b>	<b>Hazard ratio [95% CI]</b>	<b>p-value</b>
Anemia	84 (33.78)	46 (18.71)	1.92 [1.33, 2.76]	0.0005
Amputation	15 (5.99)	23 (9.33)	0.51 [0.26, 0.98]	0.0432
Dementia	4 (1.60)	12 (4.87)	0.46 [0.14, 1.57]	0.214

Event rates (%) per 10.000 person-years.

For peer review only




Figure 1A-F: Cumulative incidence of postoperative outcomes during the 9-years follow up. All-cause mortality; Congestive heart failure; Kidney disease; Malnutrition; Psychiatric disorder; Alcohol abuse.




Figure 2A-F: Cumulative incidence of postoperative adverse events during the 9-years follow-up. Gastrointestinal (GI) surgery; Abdominal pain; Bowel obstruction; Gallstone and gallbladder disease; Wound complications; Plastic surgery




## SUPPLEMENTARY MATERIAL

### Table of contents

- Flowchart – patient selection
- Methods – database linkages
- Table S1. ICD-10 codes
- Table S2. Risk estimates for men and women

### Flowchart

Selection of our data from Scandinavian Obesity Surgery Register (SOReg) before merging with data from the National Diabetes Registry (NDR).



Merging the two databases led to our study population of 5,321 patients in the SOReg who had T2DM and had undergone GBP, and 5,321 matched control patients in the NDR.

### Methods – database linkages

This study is based on data from the NDR and SOReg. Both registers are linked to Statistics Sweden at the National Board of Health and Welfare, which also stores data in the Swedish Inpatient Register (1997-2015).

We filed an application with our data and personal identity numbers [SOReg (2007-2013) & NDR (1996-2015)] to the National Board of Health and Welfare, from which all personal identity numbers have been identified and replaced by serial numbers. The coded data from the National Board of Health and Welfare were subsequently forwarded to Statistics Sweden for linkage with the Inpatient Register and LISA Database, which provides socioeconomic data. The linked data were then returned to us for validation and analysis.

**Table S1: Pre-index diagnoses and outcomes after GBP**

Diagnoses before and after gastric bypass surgery (index date) until December 2015 according to ICD-10.

Diagnosis	ICD-10	Variable origin	Registration period
Acute Myocardial infarction	<i>I21</i>	Swedish Inpatient Register	2007-2015
Coronary heart disease	<i>I20-25</i>	Swedish Inpatient Register	2007-2015
Stroke	<i>I61-64</i>	Swedish Inpatient Register	2007-2015
Cardiovascular disease	<i>I21, I61-64</i>	Swedish Inpatient Register	2007-2015
Atrial fibrillation	<i>I48</i>	Swedish Inpatient Register	2007-2015
Heart failure	<i>I50</i>	Swedish Inpatient Register	2007-2015
Valvular heart disease	<i>I05-09, I34-37, Q22, Q23</i>	Swedish Inpatient Register	2007-2015
Liver disease	<i>K70-74</i>	Swedish Inpatient Register	2007-2015
Kidney disease	<i>V42A, V45B, V56A, V56W, Z940, Z491, Z492, Z992, N17-19, N99</i>	Swedish Inpatient Register	2007-2015
Hyperglycemia	<i>E100, E101, E110, E111, E120, E121, E130, E131, E140, E141, R739</i>	Swedish Inpatient Register	2007-2015
Hypoglycemia (with or without coma)	<i>E100, E106A, E110, E110C, E110X, E116A, E120, E130, E140, E159, E160, E161W, E162, R402</i>	Swedish Inpatient Register	2007-2015
Cancer	<i>C0-9</i>	Swedish Inpatient Register	2007-2015

Dementia	<i>G300, G301, G308, G309, G31, F00-03</i>	Swedish Inpatient Register	2007-2015
Psychiatric disorders	<i>F11-19, F20-29, F30-39, F50, F55, F40-F43, F60, F61, F68, F69, F99</i>	Swedish Inpatient Register	2007-2015
Alcohol abuse	<i>F10</i>	Swedish Inpatient Register	2007-2015
Anemia	<i>D508-9, D51.0,3,8, D520</i>	Swedish Inpatient Register	2007-2015
Malnutrition	<i>E15-16, E51.2, E42-44, E46, E50-64, G63.3-4, G62.9, K91.1-2, M81.3, M83.2</i>	Swedish Inpatient Register	2007-2015
Bleeding	<i>T81.0</i>	Swedish Inpatient Register	2007-2015
Deep vein thrombosis and pulmonary embolism	<i>I80.0-9, I26, I81</i>	Swedish Inpatient Register	2007-2015
Amputation	<i>NHQ09, 11-14, 16, 17, 99, NGQ09, 19, 99, NFQ19, 99</i>	Swedish Inpatient Register	2007-2015
Bowel obstruction	<i>K56, K45</i>	Swedish Inpatient Register	2007-2015
Gastrointestinal leakage	<i>T84.4, K65.0, K63.1</i>	Swedish Inpatient Register	2007-2015
Pulmonary complications	<i>J18.0-9, J69.0, J80, J98.1</i>	Swedish Inpatient Register	2007-2015
Wound complications	<i>T81.3-4, K43.0-9</i>	Swedish Inpatient Register	2007-2015
Gastrointestinal ulcer and reflux	<i>K21, K22.1-3, K25-26, K28</i>	Swedish Inpatient Register	2007-2015
Hernia	<i>K40-43</i>	Swedish Inpatient Register	2007-2015
Gallstone, gallbladder disease and pancreatitis	<i>K80-85</i>	Swedish Inpatient Register	2007-2015
Gastrointestinal surgery not	All the operative diagnoses with	Swedish Inpatient Register	2007-2015



**Table S2: Risk estimates for men and women (Cox proportional hazards regression)**

<b>Outcome</b>	<b>Men HR with 95% CI (n=4024)</b>	<b>Women HR with 95% CI (n=6618)</b>	<b>p-value</b>
All-cause mortality	0.58 (0.45, 0.74)	0.46 (0.35, 0.60)	0.2091
Coronary heart disease	1.14 (0.90, 1.44)	1.12 (0.88, 1.42)	0.9011
Cardiovascular disease	0.63 (0.44, 0.92)	0.69 (0.49, 0.96)	0.7614
Fatal coronary heart disease	0.42 (0.24, 0.73)	0.25 (0.12, 0.54)	0.2853
Fatal cardiovascular disease	0.60 (0.32, 1.14)	0.13 (0.05, 0.36)	0.0118
Acute myocardial infarction	0.55 (0.32, 0.92)	0.56 (0.35, 0.90)	0.9522
Stroke	0.67 (0.32, 1.12)	0.88 (0.55, 1.41)	0.4429
Atrial fibrillation	1.13 (0.86, 1.47)	0.72 (0.53, 0.98)	0.0313
Heart failure	0.63 (0.46, 0.86)	0.35 (0.24, 0.51)	0.0201
Valvular heart disease	0.83 (0.38, 1.84)	0.49 (0.21, 1.13)	0.3645
Hyperglycemia	0.22 (0.09, 0.53)	0.40 (0.23, 0.69)	0.2624
Hypoglycemia with coma	0.79 (0.39, 1.63)	1.21 (0.71, 2.05)	0.3490
Dementia	0.73 (0.19, 2.86)	0.00 (.,.)	0.9991
Kidney disease	0.84 (0.28, 2.54)	0.37 (0.12, 1.13)	0.2995
Amputation	0.82 (0.36, 1.85)	0.16 (0.04, 0.72)	0.0613
Cancer	1.02 (0.69, 1.51)	0.69 (0.53, 0.90)	0.1068
Psychiatric disorder	1.02 (0.76, 1.37)	1.51 (1.23, 1.85)	0.0289
Alcohol abuse	2.87 (1.98, 4.15)	2.94 (1.85, 4.69)	0.9298
Liver diseases	0.53 (0.25, 1.13)	0.92 (0.49, 1.73)	0.2731
Anemia	1.96 (0.96, 4.01)	1.90 (1.24, 2.90)	0.9390

<b>Outcome</b>	<b>Men HR with 95% CI (n=4024)</b>	<b>Women HR with 95% CI (n=6618)</b>	<b>p-value</b>
Bleeding	9.74 (4.69, 20.22)	5.50 (3.26, 9.29)	0.2110
Deep vein thrombosis and pulmonary embolism	1.10 (0.59, 2.03)	0.96 (0.60, 1.55)	0.7455
Bowel obstruction	6.17 (3.33, 11.46)	12.10 (7.10, 20.64)	0.1035
Gastrointestinal leakage	5.28 (1.55, 18.01)	5.73 (1.96, 16.79)	0.9217
Malnutrition	2.72 (1.59, 4.67)	2.86 [1.83, 4.47]	0.8879
Pulmonary complications	0.96 (0.59, 1.56)	0.78 [0.54, 1.12]	0.4915
Wound complications	4.70 (2.79, 7.90)	3.12 [2.36, 4.13]	0.1743
Gastrointestinal ulcer and reflux	5.57 (3.49, 8.89)	5.28 (3.36, 8.31)	0.8719
Hernia	3.53 (2.19, 5.69)	2.47 (1.83, 3.33)	0.2136
Gallstone, gallbladder disease and pancreatitis	2.33 (1.59, 3.41)	2.56 (1.99, 3.30)	0.6810
Gastrointestinal surgery (not gastric bypass)	9.93 (8.35, 11.80)	7.13 (6.37, 7.98)	0.0015
Plastic surgery	16.96 (6.84, 42.07)	20.73 (12.67, 33.92)	0.7024
Abdominal pain	7.22 (4.64, 11.24)	5.12 (4.08, 6.41)	0.1703

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies***

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6,7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6,7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	6, suppl
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8, suppl
		(c) Explain how missing data were addressed	-
		(d) If applicable, explain how loss to follow-up was addressed	-
		(e) Describe any sensitivity analyses	-
<b>Results</b>			



Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	suppl
		(c) Consider use of a flow diagram	suppl
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8,20,21
		(b) Indicate number of participants with missing data for each variable of interest	-
		(c) Summarise follow-up time (eg, average and total amount)	8
Outcome data	15*	Report numbers of outcome events or summary measures over time	8,9,20,21,22,23
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9,22,23
		(b) Report category boundaries when continuous variables were categorized	9,22,23
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	suppl
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10,11,12,13,14,15
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Pros and cons of gastric bypass surgery in individuals with obesity and type 2 diabetes: nationwide, matched, observational cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023882.R2
Article Type:	Research
Date Submitted by the Author:	21-Oct-2018
Complete List of Authors:	Liakopoulos, Vasileios; Goteborgs Universitet, Department of Molecular and Clinical Medicine; Sahlgrenska universitetssjukhuset, Department of Medical Clinic Franzén, Stefan; Centre of Registers Västra Götaland; Goteborgs Universitet, Health Metrics Unit, Sahlgrenska Academy Svensson, Ann-Marie; Centre of Registers in Region Västra Götaland; Goteborgs Universitet, Department of Molecular and Clinical Medicine Miftaraj, Mervete; Center of Registers in Region Västra Götaland Ottosson, Johan ; Orebro Universitet, Department of Surgery, Faculty of Medicine and Health Näslund, Ingmar; Orebro Universitet, Department of Surgery, Faculty of Medicine and Health Gudbjornsdottir, Soffia; Goteborgs Universitet; National Diabetes Register, Centre of Registers Eliasson, Björn; University of Gothenburg, Department of Medical Clinic; Goteborgs Universitet, Department of Molecular and Clinical Medicine
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Surgery
Keywords:	DIABETES & ENDOCRINOLOGY, SURGERY, Adverse events < THERAPEUTICS

SCHOLARONE™  
Manuscripts

**TITLE PAGE**

**Complete title:** Pros and cons of gastric bypass surgery in individuals with obesity and type 2 diabetes: nationwide, matched, observational cohort study

**Authors:**

Vasileios Liakopoulos MSc <sup>1,2</sup>

Stefan Franzén PhD <sup>3,4</sup>

Ann-Marie Svensson PhD <sup>1,3</sup>

Mervete Miftaraj MSc <sup>3</sup>

Johan Ottosson, Associate professor, PhD <sup>5</sup>

Ingmar Näslund, Associate professor, PhD <sup>5</sup>

Soffia Gudbjörnsdottir, Professor, PhD <sup>1,3</sup>

Björn Eliasson, Professor, PhD <sup>1,2</sup>

**Affiliations:**

1 Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden

2 Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

3 National Diabetes Register, Centre of Registers, Gothenburg, Sweden

4 Health Metrics Unit, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

5 Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

**Corresponding author:** Vasileios Liakopoulos, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

Address SE- 413 45, Gothenburg, Sweden

Phone +46 76 112 81 32

1  
2  
3 E-mail vasileios.liakopoulos@vgregion.se  
4

5 **Keywords:** diabetes mellitus; obesity; bariatric surgery; postoperative complications; adverse  
6 effects  
7  
8

9 **Word count:** 2822  
10

11 **Number of tables:** 2  
12

13 **Number of figures:** 2  
14  
15

16  
17  
18  
19 **ABSTRACT** Word count: 300  
20

21  
22 **Objectives:** Long-term effects of gastric bypass (GBP) surgery have been presented in  
23 observational and randomized studies, but there are only limited data for persons with obesity  
24 and type 2 diabetes (T2DM) regarding postoperative complications.  
25  
26  
27  
28

29  
30 **Design:** This is a nationwide observational study based on two quality registers in Sweden  
31 (National Diabetes Register (NDR) and Scandinavian Obesity Surgery Register (SOReg)) and  
32 other national databases.  
33  
34  
35  
36

37  
38 **Setting:** After merging the data, we matched individuals with T2DM who had undergone GBP  
39 with those not surgically treated for obesity on propensity score, based on sex, age, BMI and  
40 calendar time. The risks of postoperative outcomes (rehospitalizations) were assessed using Cox  
41 regression models.  
42  
43  
44  
45  
46

47 **Participants:** We identified 5,321 patients with T2DM in the SOReg and 5,321 matched controls  
48 in the NDR, aged 18-65 years, with BMI >27.5 kg/m<sup>2</sup> and followed for up to 9 years.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

1  
2  
3 **Primary and secondary outcome measures:** We assessed risks for all-cause mortality and  
4 hospitalizations for cardiovascular disease, severe kidney disease, along with surgical and other  
5 medical conditions.  
6  
7  
8

9  
10 **Results:** The results agree with the previously suggested lower risks of all-cause mortality (49%)  
11 and cardiovascular disease (34%), and we also found positive effects for severe kidney disease  
12 but significantly increased risks (2 to 9-fold) of several short-term complications after GBP, such  
13 as abdominal pain and gastrointestinal conditions, frequently requiring surgical procedures, apart  
14 from reconstructive plastic surgery. Long-term, the risk of anemia was 92% higher, malnutrition  
15 developed approximately 3 times as often, psychiatric diagnoses were 33% more frequent and  
16 alcohol abuse was 3 times as great as in the control group.  
17  
18  
19  
20  
21  
22  
23  
24  
25

26  
27 **Conclusions:** This nationwide study confirms the benefits and describes the panorama of adverse  
28 events after bariatric surgery in persons with obesity and T2DM. Long-term postoperative  
29 monitoring and support, as better selection of patients by appropriate specialists in  
30 interdisciplinary settings, should be provided to optimize the outcomes.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- The major strength of our study is the unique and nationwide character of our population with type 2 diabetes that received gastric bypass operation.
- The high data reliability as well the external validity allow the generalizing of our results to similar developed countries using the same criteria and contraindications for bariatric surgery and quality of care.
- Our nonrandomized observational study may be limited by some minor differences between the matched groups on the propensity score.
- We tried to eliminate major confounders by careful matching between the two groups as well with an adjusted Cox regression model, however we cannot exclude underlying residual confounders.
- We studied effects and postoperative events after gastric bypass in in-patients (rehospitalizations) leaving unassessed a large proportion of out-patients visiting the primary care.

## MAIN TEXT

### Introduction

The most effective method for ensuring long-term weight reduction in individuals with obesity as well as beneficial effects on mortality, cardiovascular disease (CVD) and CV risk factors is bariatric surgery, Roux-en-Y gastric bypass (GBP) in particular (1, 2). These effects of GBP have also been shown in patients with type 2 diabetes (T2DM) in both observational (3-5) and randomized control trials (6-8) under different follow-up periods. However, it has also been demonstrated in cohorts with a low proportion of individuals with diabetes that GBP is associated with postoperative complications and readmission rates from 0.6% to 11.3% (9-12), as well as long-term adverse outcomes such as hypoglycemia (6), anemia, nutritional deficiencies (13), gallstones (14), depression (15), suicide and non-fatal self-harm (16) and alcohol problems (17).

Only few reports have addressed the long-term incidence of complications in patients with obesity and T2DM who have undergone bariatric surgery. The Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently (STAMPEDE) study reported adverse events of GBP and sleeve gastrectomy compared to conventional medical therapy, but only in 142 individuals with T2DM randomized at a single center with follow-up period up to 5 years (6). Similarly, the Diabetes Surgery Study recently reported clinical effects and adverse events after GBP or lifestyle–medical management in 120 individuals after 5 years (18). Larger prospective studies such as Swedish Obese Subjects (SOS) study (1) and large American observational studies with broad samples (10, 19) have addressed postoperative outcomes and

1  
2  
3 readmission rates of GBP or other types of bariatric surgery, but with only a small proportion of  
4  
5 patients who have T2DM.  
6

7  
8 We recently conducted a nationwide observational study of individuals with T2DM who  
9  
10 underwent GBP compared with matched individuals and reported beneficial effects on overall  
11  
12 mortality and cardiovascular events (3), but we did not address short-term or long-term adverse  
13  
14 effects. The objective of this observational cohort study is therefore to identify clinical benefits as  
15  
16 well as a wide spectrum of early postoperative, as well as long-term, adverse effects of GBP for  
17  
18 up to 9 years in individuals with T2DM compared to individuals with obesity who have not  
19  
20 received surgical treatment.  
21  
22  
23

## 24 25 **Research Design and Methods**

26  
27  
28  
29 This study is based on two nationwide quality registers in Sweden: the National Diabetes  
30  
31 Register (NDR) and the Scandinavian Obesity Surgery Register (SOReg), as well as linked data  
32  
33 from the Swedish Inpatient Register, the Cause of Death Register and the Statistics Sweden. All  
34  
35 these databases have previously been described and validated (20, 21). The NDR is a quality  
36  
37 register tool that provides nearly full coverage (90% for T2DM and 95% for T1DM) of Swedes  
38  
39 with diabetes since 1996. SOReg started in 2007 as a quality and research register. Since 2010, it  
40  
41 has covered virtually all bariatric procedures in Sweden. All bariatric centers report to the register  
42  
43 (surgical complications, postoperative reports and longitudinal effects). All individuals provided  
44  
45 informed consent before being included in the NDR and SOReg registries. The regional ethical  
46  
47 review board at the University of Gothenburg, Sweden, approved the study.  
48  
49  
50

51  
52  
53 After merging the data of SOReg and NDR, we identified individuals with diabetes and obesity  
54  
55 who had undergone primary GBP between January 1, 2007 and December 31, 2015 (see  
56  
57  
58  
59  
60



1  
2  
3 Supplementary material). We subsequently matched them with control patients in the NDR who  
4 had not undergone bariatric surgery. Propensity score matching (1:1) was performed on the basis  
5 of sex, age (18-75 years), body mass index (BMI) ( $>27.5$  kg/m<sup>2</sup>) and calendar time.  
6  
7

8  
9  
10 We based our definition of T2DM on classical epidemiological criteria, i.e., treatment with diet,  
11 oral antihyperglycemic agents, insulin or different combinations, as well as patients who were  
12  $\geq 40$  years of age at the time of diagnosis.  
13  
14  
15

16  
17  
18 All clinical characteristics at baseline were obtained from the NDR and SOReg, socioeconomic  
19 status was taken from Statistics Sweden, and presurgical and postsurgical diagnoses were taken  
20 from the Swedish Inpatient Register (ICD-10) (Table S1, supplementary material), which are  
21 held by the National Board of Health and Welfare. The Inpatient Registry records all inpatient  
22 admissions since 1987. We studied admissions to the hospitals by including specific diagnoses  
23 for coronary heart disease, acute myocardial infarction, stroke, atrial fibrillation, heart failure and  
24 valvular heart disease, as well as acute and chronic diseases that were related to diabetes mellitus  
25 (hyperglycemia, hypoglycemia with coma, amputation, kidney, liver and pulmonary diseases,  
26 cancer, anemia, malnutrition, dementia, psychiatric disorders and alcohol abuse). We also report  
27 surgical history, such as hospitalization due to bleeding, gastrointestinal (GI) surgery and  
28 leakage, wound complications, GI ulcers and reflux disease, bowel obstruction, hernia, gall  
29 bladder disease and pancreatitis, as well previous plastic surgery.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 Patients were followed up to 9 years or until the first admission to the hospital for specific  
48 diagnoses or group of diagnoses or death. Controls who were treated with GBP were censored on  
49 the date of such treatment.  
50  
51  
52  
53

## 54 **Statistical analysis**

55  
56  
57  
58  
59  
60

1  
2  
3 One matched control was selected for each GBP patient using propensity scores for longitudinal  
4 exposure (22). The outcome of the propensity score matching was assessed only through  
5  
6 descriptive statistics comparing the matched groups. Thus, controls were matched to GBP  
7  
8 patients based on the estimated risk score from a Cox regression model with time-updated data,  
9  
10 where exposure for GBP was the endpoint. The model contained covariates for sex, age and BMI.  
11  
12 Controls were selected in chronological order.  
13  
14  
15

16  
17 Descriptive statistics are presented using means with standard deviation for age and BMI, median  
18 with quartiles for income and counts with percentages for all other variables. Incidence rates for  
19  
20 each outcome were estimated using counts and person-years. Comparisons between GBP patients  
21  
22 and controls used Cox regression, adjusted for sex, age, BMI and socioeconomic factors (income,  
23  
24 marital status, education level and country of origin). No adjustments were made for multiple  
25  
26 inferences. Thus, while p-values below 5% were considered statistically significant, the outcome  
27  
28 of individual hypothesis tests should be interpreted with caution.  
29  
30  
31  
32  
33

### 34 **Patient and Public Involvement Statement**

35  
36  
37 The authors developed the research question and outcome measures. The patients and public  
38  
39 were not involved in the design or conduct of the study. The results will be disseminated to study  
40  
41 participants via media and health centres.  
42  
43  
44

### 45 **Results**

46  
47  
48 We identified 5,321 patients in the SOReg who had T2DM and had undergone GBP (96.0%  
49  
50 laparoscopic, 1.7% initially laparoscopic and converted to open surgery, and 2.3% primary open  
51  
52 surgery), as well as 5,321 matched controls in the NDR (flowchart, supplementary material).  
53  
54  
55 Both groups were followed for up to 9 years (mean, 4.5 years). Table 1 shows the baseline  
56  
57  
58  
59  
60

1  
2  
3 characteristics of both groups. There were some minor differences between the groups  
4  
5 (standardized differences of more than 0.1): the GBP persons had a slightly higher mean age and  
6  
7 BMI and were less likely to be single (marital status), with a greater mean income and higher  
8  
9 educational level. The groups were well matched with respect to previous cardiovascular,  
10  
11 gastrointestinal, psychiatric and surgical diseases (standardized differences less than 0.1).  
12  
13

14  
15 Table 2 shows the number of events and incidence rates during the follow-up period. Event rates  
16  
17 for all-cause mortality were 72.9 and 142.1 per 10.000 person-years in GBP and the control  
18  
19 group respectively (HR 0.51, 95% CI 0.43-0.62; Figure 1A). Risks for cardiovascular or coronary  
20  
21 heart disease, acute myocardial infarction and congestive heart failure (Figure 1B) were also  
22  
23 lower after GBP.  
24  
25

26  
27 Other benefits were observed after GBP. Hospitalization for hyperglycemia was less frequent,  
28  
29 and the risks of kidney disease (Figure 1C), leg amputation and cancer were lower (Table 2).  
30  
31 GBP individuals were, however, at greater risk for anemia (HR 1.92, 95% CI 1.33-2.76) and  
32  
33 malnutrition (HR 2.81, 95% CI 1.98-3.97) (Figure 1D). The risks of hospitalization due to  
34  
35 psychiatric disorders or alcohol abuse (Figure 1E-F) increased after GBP (73.1 and 26.5 per  
36  
37 10.000 person-years in GBP and the control group respectively, HR 1.33, 95% CI 1.13-1.58 and  
38  
39 HR 2.90, 95% CI 2.16-3.88).  
40  
41  
42  
43

44  
45 A number of adverse conditions, frequently necessitating additional gastrointestinal surgery, were  
46  
47 also observed more often in the GBP group: abdominal pain, bowel obstruction, gallstones,  
48  
49 gallbladder disease, pancreatitis, gastrointestinal ulcers, reflux, hernia, gastrointestinal leakage,  
50  
51 wound complications and bleeding (Figure 2A-E). Subsequent reconstructive plastic surgery  
52  
53 (Figure 2F) was also required frequently, while the risk for pulmonary complications, embolism,  
54  
55 deep vein thrombosis or liver disease was slightly lower.  
56  
57  
58  
59  
60

1  
2  
3 We analyzed results of GBP treatment in men and women using a Cox regression model adjusted  
4 for sex, age, BMI and socioeconomic factors (Table S2, supplementary material). The significant  
5 interactions we noted were risks for fatal CVD, atrial fibrillation, congestive heart failure and  
6 gastrointestinal surgery (higher in men after GBP,  $p < 0.05$ ), while women were at a higher risk  
7 (1.51, 95%CI 1.23-1.85) of being hospitalized due to a psychiatric disorder after GBP.  
8  
9  
10  
11  
12  
13

## 14 15 **Discussion**

16  
17  
18 This observational study compares outcomes after GBP (rehospitalizations) in individuals with  
19 obesity and TDM2 with a matched group of those who have not been surgically treated. We  
20 confirm the previously shown beneficial effects on all-cause mortality and cardiovascular  
21 morbidity in individuals with or without T2DM (1, 3), as well as presenting a panorama of short-  
22 term and long-term complications after GBP on a nationwide scale. Common reasons for  
23 postoperative hospital admissions were gastrointestinal conditions such as abdominal pain,  
24 gallstone/gallbladder disease, pancreatitis, gastrointestinal ulcer, leakage, reflux, hernia, bowel  
25 obstruction, psychiatric disorders and alcohol abuse.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 Additional gastrointestinal surgery was performed in 17.6% of the GBP group, more than three  
39 times as much as in the control group. Gastrointestinal leakage, bleeding, abdominal pain and  
40 bowel obstruction are likely causes for these surgical interventions, as well as gallstone disease  
41 and cholecystitis, which are frequently observed after GBP and rapid weight loss (14, 23-25).  
42  
43  
44  
45  
46

47 Wanjura et al. recently showed that the incidence of cholecystectomy was substantially elevated  
48 before GBP and increased 6-36 months after surgery compared with the general population (24).  
49 Previous GBP doubled the risk of complications after cholecystectomy, almost quadrupled the  
50 risk of reoperation (24) and the simultaneous cholecystectomy increased the risk by increasing of  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 the operation time (25). It has been suggested that defective gallbladder emptying in conjunction  
4 with the production of crystallization-promoting compounds (mucin) can contribute to the  
5 development of cholesterol crystals and gallstones in subjects with obesity during weight  
6 reduction (23).  
7  
8  
9  
10  
11

12 Some postoperative complications were common shortly after GBP (leakage, wound  
13 complications and ulcer/reflux), while others (hernia, bowel obstruction and gallstone) generally  
14 increased after 1-2 years. These findings were expected, although the incidence of ulcers and  
15 reflux disease soon after GBP may be exaggerated due to the endoscopies for dyspepsia and  
16 dysphoric symptoms. Hernias may well be undiagnosed preoperatively but detected during  
17 surgery and become symptomatic after weight loss when the associated fat disappears. The  
18 incidence of wound complications and gastrointestinal leakage shortly after GBP was comparable  
19 to other studies with short follow-up periods and a small percentage of patients with diabetes (26-  
20 28). There were no major differences between men and women in the risk for specific  
21 postoperative complications, apart from a slightly higher incidence of additional surgical  
22 procedures and cardiovascular risk (fatal CVD) in men, as previously suggested (11, 29).  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 There was a 42% lower relative risk of hospitalization due to severe kidney disease after GBP. A  
40 systematic review has previously suggested that weight loss is associated with reductions in  
41 proteinuria and microalbuminuria. A retrospective cohort study showed a higher mean estimated  
42 glomerular filtration rate (eGFR) in patients up to three years after bariatric surgery than those  
43 with moderately impaired renal function (CKD stages 3 and 4) who were referred for, but did not  
44 receive, surgery (30, 31). There has been no prospective study in patients with severe renal  
45 disease. Retrospective data are limited by study design and estimations of renal function. eGFR  
46 calculations depend on muscle mass and serum creatinine levels, both of which change after  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 weight loss independent of kidney function. Although the selection of patients eligible for  
4 bariatric surgery can contribute to the apparent beneficial effects on risk of severe kidney disease,  
5 these results should prompt new studies concerning the effects on renal function, as well as  
6 optimal patients for surgery to treat weight loss. Improved glycemic and blood pressure control  
7 after GBP (32, 33) could also contribute to the apparent effects of including changes in dose of  
8 antihypertensives, which are known to affect serum creatinine. We did not evaluate glycemic  
9 control in this study, but pronounced effects after bariatric surgery have been demonstrated  
10 repeatedly (6, 34, 35).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 The anatomical and physiological consequences of GBP result in a higher risk of long-term  
23 deficiencies of several vitamins and minerals (36). The present study had no access to data from  
24 primary care, where follow-up should start 2 years after GBP, but malnutrition and anemia were  
25 twice as common. Poor compliance with vitamin and mineral supplements, as well as irregular  
26 follow-up, may very likely explain these results. A recent meta-analysis pointed to this potential  
27 problem in individuals without diabetes, suggesting that diabetes is not a risk factor per se (13).  
28 Adequate supplementation is paramount (37), since deficiencies after GBP tend to increase over  
29 time (13, 38).  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 A history of psychiatric disorders requiring hospitalization was not uncommon in either group of  
42 individuals with obesity in this study, and was 33% higher after GBP. Previous studies have  
43 shown that depression, which may improve in the first year following bariatric surgery, tends to  
44 progress (39) along with suicide and self-harm, particularly if they are preexisting conditions (15,  
45 16). Thus, greater awareness is needed in order to identify vulnerable patients with a history  
46 of self-harm or depression who may need psychiatric services after GBP. Perhaps specific  
47 multidisciplinary teams should identify such patients and through treatment algorithms could  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 enhance the safety and efficacy pre and postoperatively (40). In agreement with previous studies  
4  
5 (17, 41) we confirmed a higher event rate of alcohol-related problems that lead to hospitalization  
6  
7 after GBP, which points to the importance of careful selection of patients who are offered  
8  
9 surgery, as well as better follow-up of those with a history of alcohol-related risk behavior. The  
10  
11 mechanisms of this well-known phenomenon are still unknown.  
12  
13

14  
15 The indications for surgical treatment of obesity were presented by the National Institute of  
16  
17 Health in 1991 (42) and have been repeatedly revised and expanded over the years. Severe and  
18  
19 untreated psychopathology as well as active alcohol or substance abuse, or eating disorders are  
20  
21 contraindications to bariatric surgery, although the decision to offer this treatment should always  
22  
23 be individualized based on the stability of conditions and the assessment of multidisciplinary  
24  
25 treatment teams (43). The need for more robust criteria and the possible application of scoring  
26  
27 systems or algorithms that could facilitate the assessment of patients beyond BMI has been  
28  
29 discussed (44).  
30  
31  
32  
33

34 A major strength of this study is its nationwide coverage of patients with obesity and type 2  
35  
36 diabetes, all of whom received recent Roux-en-Y gastric bypass surgery. The results are likely to  
37  
38 be generalizable to similar developed countries using the same criteria and contraindications for  
39  
40 bariatric surgery and quality of care. All linked databases are characterized by high participation  
41  
42 rates and validation of medical data (21, 45).  
43  
44  
45

46 Our study was nonrandomized and observational, but with carefully matched groups to maximize  
47  
48 the size of the cohort as well as to reduce the influence of confounding factors. Minor differences  
49  
50 in clinical characteristics may still influence our results, and we also did not include some  
51  
52 variables (e.g. duration of diabetes, HbA1c, use of antidiabetic drugs) that potentially also could  
53  
54 affect the results. Similarly, we did not exclude patients with multiple comorbidities before the  
55  
56  
57  
58

1  
2  
3 intervention, because we would have lost substantial data and they had all qualified for GBP. We  
4  
5 also used Cox proportional hazards regression modelling, including baseline characteristics, to  
6  
7 minimize the effects of confounding. Certainly, we cannot rule out residual confounding,  
8  
9 unobserved factors that may be related to both exposure and outcome. However, the external  
10  
11 validity is most likely high as our study includes virtually all GBP patients with type 2 diabetes in  
12  
13 Sweden during the time period.  
14  
15

16  
17 Another limitation is that we captured diagnoses during hospitalization, not outpatient care.  
18  
19 Comorbidities and incidence of postoperative outcomes may be underestimated as a result, but  
20  
21 the systematic flaw could not be avoided. Nevertheless, measurement errors may potentially arise  
22  
23 because the patients who had received surgery were followed up more frequently than the control  
24  
25 group. GBP was the only surgical procedure we studied (96% laparoscopic), given that sleeve  
26  
27 gastrectomy and duodenal switch were not performed very often and follow-up data were too  
28  
29 limited during the study period. We also did not address the importance of more specific surgical  
30  
31 techniques.  
32  
33  
34  
35

36  
37 Individuals with obesity and type 2 diabetes who have undergone GBP are generally at a reduced  
38  
39 risk of all-cause mortality and cardiovascular morbidity, as well as severe kidney disease and  
40  
41 cancer to a lesser extent. They also have, however, significantly higher risks of postoperative  
42  
43 complications and adverse events both short-term and long-term, mostly abdominal pain and  
44  
45 gastrointestinal conditions that frequently require additional surgical procedures, apart from  
46  
47 reconstructive plastic surgery. Long-term consequences observed more often are anemia,  
48  
49 malnutrition, psychiatric disorders and alcohol abuse. In order to maximize the benefit and  
50  
51 minimize the risk of problems, long-term postoperative monitoring and support should be  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 provided. Better selection of patients for such treatment, performed by appropriate specialists in  
4  
5 interdisciplinary settings, could probably also optimize outcomes.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 **Author Contributions:** VL, SF, AMS, MM, JO, IN, SG and BE contributed to the conception  
18 and design of the study. SF, MM, AMS, JO and IN contributed to the acquisition of data and SF  
19 performed the statistical analyses. All authors contributed to the interpretation of data. VL and  
20 BE drafted the article, and VL, SF, AMS, MM, JO, IN, SG and BE contributed to critical  
21 revision. BE is the guarantor of this work, had full access to the data and assumes responsibility  
22 for their integrity and analysis.  
23  
24  
25  
26  
27  
28  
29  
30

31 **Competing of interest:** All authors have completed the ICMJE uniform disclosure form at  
32 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for the  
33 submitted work; no financial relationships with any organisations that might have an interest in  
34 the submitted work in the previous three years; no other relationships or activities that could  
35 appear to have influenced the submitted work.  
36  
37  
38  
39  
40  
41  
42  
43

44 **Funding:** The Swedish Association of Local Authorities and Regions funds the National  
45 Diabetes Register and the Scandinavian Obesity Surgery Register. Region Västra Götaland also  
46 provides funding for the NDR.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Data sharing statement:** This is a registry study and therefore the data generated is not suitable for sharing beyond that contained within the report. Further information can be obtained from the corresponding author.

**Ethical Approval:** Ethics Review Board of the University of Gothenburg approved this study.

## References

1. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. *The New England journal of medicine*. 2007;357(8):741-52.
2. Kwok CS, Pradhan A, Khan MA, Anderson SG, Keavney BD, Myint PK, et al. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. *International journal of cardiology*. 2014;173(1):20-8.
3. Eliasson B, Liakopoulos V, Franzen S, Naslund I, Svensson AM, Ottosson J, et al. Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. *The lancet Diabetes & endocrinology*. 2015;3(11):847-54.
4. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. *The American journal of medicine*. 2009;122(3):248-56. e5.
5. Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. *Jama*. 2014;311(22):2297-304.
6. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. *The New England journal of medicine*. 2017;376(7):641-51.
7. Cummings DE, Arterburn DE, Westbrook EO, Kuzma JN, Stewart SD, Chan CP, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. *Diabetologia*. 2016;59(5):945-53.
8. Ikramuddin S, Billington CJ, Lee WJ, Bantle JP, Thomas AJ, Connett JE, et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. *The lancet Diabetes & endocrinology*. 2015;3(6):413-22.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
9. Saunders JK, Ballantyne GH, Belsley S, Stephens D, Trivedi A, Ewing DR, et al. 30-day readmission rates at a high volume bariatric surgery center: laparoscopic adjustable gastric banding, laparoscopic gastric bypass, and vertical banded gastroplasty-Roux-en-Y gastric bypass. *Obesity surgery*. 2007;17(9):1171-7.
10. Berger ER, Huffman KM, Fraker T, Petrick AT, Brethauer SA, Hall BL, et al. Prevalence and Risk Factors for Bariatric Surgery Readmissions: Findings From 130,007 Admissions in the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program. *Ann Surg*. 2018 Jan;267(1):122-31.
11. Dayer-Jankechova A, Fournier P, Allemann P, Suter M. Complications After Laparoscopic Roux-en-Y Gastric Bypass in 1573 Consecutive Patients: Are There Predictors? *Obesity surgery*. 2016;26(1):12-20.
12. Bruze G, Ottosson J, Neovius M, Naslund I, Marsk R. Hospital admission after gastric bypass: a nationwide cohort study with up to 6 years follow-up. *Surg Obes Relat Dis*. 2017;13(6):962-9.
13. Weng TC, Chang CH, Dong YH, Chang YC, Chuang LM. Anaemia and related nutrient deficiencies after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis. *BMJ open*. 2015;5(7):e006964.
14. Melmer A, Sturm W, Kuhnert B, Engl-Prosch J, Ress C, Tschoner A, et al. Incidence of Gallstone Formation and Cholecystectomy 10 Years After Bariatric Surgery. *Obesity surgery*. 2015;25(7):1171-6.
15. Lagerros YT, Brandt L, Hedberg J, Sundbom M, Boden R. Suicide, Self-harm, and Depression After Gastric Bypass Surgery: A Nationwide Cohort Study. *Ann Surg*. 2017;265(2):235-43.
16. Neovius M, Bruze G, Jacobson P, Sjöholm K, Johansson K, Granath F, et al. Risk of suicide and non-fatal self-harm after bariatric surgery: results from two matched cohort studies. *Lancet Diabetes Endocrinol*. 2018;6(3):197-207.
17. Svensson PA, Anveden A, Romeo S, Peltonen M, Ahlin S, Burza MA, et al. Alcohol consumption and alcohol problems after bariatric surgery in the Swedish obese subjects study. *Obesity (Silver Spring, Md)*. 2013;21(12):2444-51.
18. Ikramuddin S, Korner J, Lee WJ, Thomas AJ, Connett JE, Bantle JP, et al. Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study. *Jama*. 2018;319(3):266-78.
19. Shin JH, Worni M, Castleberry AW, Pietrobon R, Omotosho PA, Silberberg M, et al. The application of comorbidity indices to predict early postoperative outcomes after laparoscopic Roux-en-Y gastric bypass: a nationwide comparative analysis of over 70,000 cases. *Obesity surgery*. 2013;23(5):638-49.
20. Eliasson B, Gudbjornsdottir S. Diabetes care--improvement through measurement. *Diabetes research and clinical practice*. 2014;106 Suppl 2:S291-4.
21. Hedenbro JL, Naslund E, Boman L, Lundegardh G, Bylund A, Ekelund M, et al. Formation of the Scandinavian Obesity Surgery Registry, SOReg. *Obesity surgery*. 2015;25(10):1893-900.
22. Lu B. Propensity score matching with time-dependent covariates. *Biometrics*. 2005;61(3):721-8.
23. Gustafsson U, Benthin L, Granstrom L, Groen AK, Sahlin S, Einarsson C. Changes in gallbladder bile composition and crystal detection time in morbidly obese subjects after bariatric surgery. *Hepatology*. 2005;41(6):1322-8.
24. Wanjura V, Sandblom G, Osterberg J, Enochsson L, Ottosson J, Szabo E. Cholecystectomy after gastric bypass-incidence and complications. *Surg Obes Relat Dis*. 2017;13(6):979-87.
25. Wanjura V, Szabo E, Osterberg J, Ottosson J, Enochsson L, Sandblom G. Morbidity of cholecystectomy and gastric bypass in a national database. *Br J Surg*. 2018;105(1):121-7.
26. Stenberg E, Szabo E, Agren G, Naslund E, Boman L, Bylund A, et al. Early complications after laparoscopic gastric bypass surgery: results from the Scandinavian Obesity Surgery Registry. *Ann Surg*. 2014;260(6):1040-7.

- 1
- 2
- 3
- 4 27. Maciejewski ML, Winegar DA, Farley JF, Wolfe BM, DeMaria EJ. Risk stratification of serious
- 5 adverse events after gastric bypass in the Bariatric Outcomes Longitudinal Database. *Surg Obes Relat Dis.*
- 6 2012;8(6):671-7.
- 7 28. Yong PH, Weinberg L, Torkamani N, Churilov L, Robbins RJ, Ma R, et al. The Presence of Diabetes
- 8 and Higher HbA1c Are Independently Associated With Adverse Outcomes After Surgery. *Diabetes Care.*
- 9 2018;41(6):1172-9.
- 10 29. Livingston EH, Huerta S, Arthur D, Lee S, De Shields S, Heber D. Male gender is a predictor of
- 11 morbidity and age a predictor of mortality for patients undergoing gastric bypass surgery. *Ann Surg.*
- 12 2002;236(5):576-82.
- 13 30. Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN. Weight loss and proteinuria: systematic
- 14 review of clinical trials and comparative cohorts. *Nephrol Dial Transplant.* 2010;25(4):1173-83.
- 15 31. Imam TH, Fischer H, Jing B, Burchette R, Henry S, DeRose SF, et al. Estimated GFR Before and
- 16 After Bariatric Surgery in CKD. *American journal of kidney diseases : the official journal of the National*
- 17 *Kidney Foundation.* 2017;69(3):380-8.
- 18 32. Sjöström L, Lindroos A-K, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle,
- 19 diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *New England Journal of*
- 20 *Medicine.* 2004;351(26):2683-93.
- 21 33. Courcoulas AP, King WC, Belle SH, Berk P, Flum DR, Garcia L, et al. Seven-Year Weight
- 22 Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study.
- 23 *JAMA Surg.* 2018;153(5):427-34.
- 24 34. Liakopoulos V, Franzén S, Svensson A-M, Zethelius B, Ottosson J, Näslund I, et al. Changes in risk
- 25 factors and their contribution to reduction of mortality risk following gastric bypass surgery among
- 26 obese individuals with type 2 diabetes: a nationwide, matched, observational cohort study. *BMJ Open*
- 27 *Diabetes Research & Care.* 2017;5(1).
- 28 35. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaiconelli A, Nanni G, et al. Bariatric-metabolic
- 29 surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up
- 30 of an open-label, single-centre, randomised controlled trial. *Lancet (London, England).*
- 31 2015;386(9997):964-73.
- 32 36. Shah M, Simha V, Garg A. Review: long-term impact of bariatric surgery on body weight,
- 33 comorbidities, and nutritional status. *J Clin Endocrinol Metab.* 2006;91(11):4223-31.
- 34 37. Ziegler O, Sirveaux MA, Brunaud L, Reibel N, Quilliot D. Medical follow up after bariatric surgery:
- 35 nutritional and drug issues. General recommendations for the prevention and treatment of nutritional
- 36 deficiencies. *Diabetes Metab.* 2009;35(6 Pt 2):544-57.
- 37 38. Olbers T, Beamish AJ, Gronowitz E, Flodmark CE, Dahlgren J, Bruze G, et al. Laparoscopic Roux-
- 38 en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish
- 39 nationwide study. *The lancet Diabetes & endocrinology.* 2017;5(3):174-83.
- 40 39. Mitchell JE, King WC, Chen JY, Devlin MJ, Flum D, Garcia L, et al. Course of depressive symptoms
- 41 and treatment in the longitudinal assessment of bariatric surgery (LABS-2) study. *Obesity (Silver Spring).*
- 42 2014;22(8):1799-806.
- 43 40. Spittal MJ, Fruhbeck G. Bariatric surgery: many benefits, but emerging risks. *Lancet Diabetes*
- 44 *Endocrinol.* 2018;6(3):161-3.
- 45 41. King WC, Chen JY, Mitchell JE, Kalarchian MA, Steffen KJ, Engel SG, et al. Prevalence of alcohol
- 46 use disorders before and after bariatric surgery. *Jama.* 2012;307(23):2516-25.
- 47 42. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference
- 48 Panel. *Ann Intern Med.* 1991;115(12):956-61.
- 49 43. De Luca M, Angrisani L, Himpens J, Busetto L, Scopinaro N, Weiner R, et al. Indications for
- 50 Surgery for Obesity and Weight-Related Diseases: Position Statements from the International Federation
- 51 for the Surgery of Obesity and Metabolic Disorders (IFSO). *Obes Surg.* 2016;26(8):1659-96.
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1  
2  
3 44. Fruhbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. *Nat Rev*  
4 *Endocrinol.* 2015;11(8):465-77.

5 45. Emilsson L, Lindahl B, Koster M, Lambe M, Ludvigsson JF. Review of 103 Swedish Healthcare  
6 Quality Registries. *J Intern Med.* 2015;277(1):94-136.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17

18 **Figure legends:**

19  
20 **Figure 1A-F:** Cumulative incidence of postoperative outcomes during the 9-years follow up. All-  
21 cause mortality; Congestive heart failure; Kidney disease; Malnutrition; Psychiatric disorder;  
22 Alcohol abuse.  
23  
24

25  
26 **Figure 2A-F:** Cumulative incidence of postoperative adverse events during the 9-years follow-  
27 up. Gastrointestinal (GI) surgery; Abdominal pain; Bowel obstruction; Gallstone and gallbladder  
28 disease; Wound complications; Plastic surgery.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<b>Table 1. Baseline characteristics</b>			
	<b>GBP (n=5321)</b>	<b>Control (n=5321)</b>	<b>Standardized difference*</b>
Sex			
Men	2098 (39.4%)	1926 (36.2%)	0.0471
Women	3223 (60.5%)	3395 (63.8%)	0.0471
Age	49.0 (9.5)	47.1 (11.5)	0.122
BMI	42.0 (5.7)	40.9 (7.3)	0.117
Income (SEK)	199.638 (139136; 261558)	168.380 (121840; 239368)	0.156
Marital status			
Single	1602 (30.1%)	2064 (38.8%)	0.130
Married	2518 (47.4%)	2227 (41.9%)	0.0781
Separated	1092 (20.5%)	881 (16.6%)	0.0723
Widowed	106 (2.0%)	147 (2.8%)	0.0358
Education level			
Compulsory school	1069 (20.1%)	1431 (26.9%)	0.114
University	3192 (60.0%)	2847 (53.5%)	0.0926
Upper secondary school	1037 (19.5%)	930 (17.5%)	0.0366
Missing data	23 (0.4%)	113 (2.1%)	0.107
Country of origin			
Sweden	4261 (80.1%)	4027 (75.7%)	0.075
Rest of Europe	514 (9.7%)	602 (11.3%)	0.0382
Rest of the world	546 (10.3%)	692 (13.0%)	0.0607
Cardiovascular			
Cardiovascular disease	273 (5.1%)	261 (4.9%)	0.00730
Acute myocardial infarction	173 (3.2%)	169 (3.2%)	0.00301
Coronary heart disease	395 (7.4%)	313 (5.9%)	0.0437
Congestive heart failure	140 (2.6%)	168 (3.2%)	0.0222

Atrial fibrillation	148 (2.8%)	149 (2.8%)	0.000807
Valvular heart disease	24 (0.4%)	27 (0.5%)	0.00577
Stroke	109 (2.0%)	103 (1.9%)	0.00571
Deep vein thrombosis/pulmonary embolism	71 (1.3%)	65 (1.2%)	0.00710
Diabetes-related			
Hyperglycemia	80 (1.5%)	130 (2.4%)	0.0478
Hypoglycemia (with or without coma)	57 (1.1%)	61 (1.2%)	0.00508
Gastrointestinal			
Gastrointestinal surgery (not gastric bypass)	549 (10.3%)	644 (12.1%)	0.0400
Abdominal pain	386 (7.2%)	334 (6.3%)	0.0275
Gallstone, gallbladder disease and pancreatitis	419 (7.9%)	366 (6.9%)	0.0270
Gastrointestinal ulcer and reflux	86 (1.6%)	72 (1.4%)	0.0154
Hernia	204 (3.8%)	160 (3.0%)	0.0322
Bowel obstruction	18 (0.3%)	29 (0.6%)	0.0220
Gastrointestinal leakage	7 (0.1%)	17 (0.3%)	0.0280
Liver disease	16 (0.3%)	26 (0.5%)	0.0212
Surgical			
Plastic surgery	54 (1.0%)	33 (0.6%)	0.0310
Wound complications	192 (3.6%)	156 (2.9%)	0.0269
Bleeding	50 (0.9%)	32 (0.6%)	0.0273
Other			
Psychiatric disorders	318 (6.0%)	346 (6.5%)	0.0154
Alcohol abuse	94 (1.8%)	122 (2.3%)	0.0264
Cancer	111 (2.1%)	158 (3.0%)	0.0398
Malnutrition	21 (0.4%)	41 (0.8%)	0.0349
Kidney disease	56 (1.0%)	83 (1.6%)	0.0316
Pulmonary disease	128 (2.4%)	131 (2.5%)	0.00259
Anemia	55 (1.0%)	60 (1.1%)	0.00643
Amputation	10 (0.2%)	12 (0.2%)	0.00585
Dementia	1 (0.02%)	4 (0.08%)	0.0184

Numbers and proportions.

\*Difference between sample means divided by standard deviation. Acceptable significance when standardized difference <0.1.

<b>Table 2. Number of events and event rates during follow up</b>				
<b>Outcome</b>	<b>GBP (n=5321)</b>	<b>Control (n=5321)</b>	<b>Hazard ratio [95% CI]</b>	<b>p-value</b>
All-cause mortality	183 (72.90)	351 (142.06)	0.51 [0.43, 0.62]	<.0001
Cardiovascular				
Cardiovascular disease	108 (43.54)	150 (61.54)	0.66 [0.51, 0.85]	0.0014
Fatal cardiovascular disease	21 (8.38)	64 (25.94)	0.34 [0.20, 0.56]	<.0001
Acute myocardial infarction	51 (20.43)	85 (34.69)	0.55 [0.39, 0.79]	0.0010
Coronary heart disease	309 (128.66)	274 (114.28)	1.13 [0.95, 1.34]	0.156
Fatal coronary heart disease	28 (11.17)	77 (31.20)	0.35 [0.22, 0.54]	<.0001
Congestive heart failure	109 (43.94)	225 (93.05)	0.49 [0.39, 0.62]	<.0001
Atrial fibrillation	204 (83.64)	213 (88.16)	0.93 [0.76, 1.14]	0.486
Valvular heart disease	21 (8.39)	32 (13.00)	0.64 [0.36, 1.14]	0.131
Stroke	59 (23.69)	71 (28.94)	0.77 [0.54, 1.10]	0.158
Deep vein thrombosis/pulmonary embolism	56 (22.48)	59 (24.07)	1.01 [0.69, 1.48]	0.952
Diabetes-related				
Hypoglycemia (with or without coma)	43 (17.24)	46 (18.72)	1.04 [0.68, 1.60]	0.844
Hyperglycemia	23 (9.20)	89 (36.37)	0.33 [0.21, 0.53]	<.0001
Gastrointestinal				
Gastrointestinal surgery (not gastric bypass)	936 (422.59)	301 (125.76)	3.33 [2.91, 3.80]	<.0001
Abdominal pain	558 (239.25)	124 (50.94)	5.52 [4.51, 6.75]	<.0001
Gallstone, gallbladder disease and pancreatitis	312 (129.31)	125 (51.30)	2.49 [2.02, 3.08]	<.0001
Gastrointestinal ulcer and reflux	239 (98.58)	46 (18.73)	5.42 [3.91, 7.51]	<.0001
Hernia	235 (97.00)	86 (35.17)	2.75 [2.14, 3.54]	<.0001
Bowel obstruction	232 (95.29)	27 (10.97)	9.47 [6.31, 14.20]	<.0001



**Table 2. Number of events and event rates during follow up**

<b>Outcome</b>	<b>GBP (n=5321)</b>	<b>Control (n=5321)</b>	<b>Hazard ratio [95% CI]</b>	<b>p-value</b>
Gastrointestinal leakage	40 (16.05)	7 (2.84)	5.54 [2.46, 12.45]	<.0001
Liver disease	30 (12.00)	40 (16.26)	0.73 [0.45, 1.19]	0.205
<b>Surgical</b>				
Plastic surgery	380 (158.08)	22 (8.94)	19.85 [12.86, 30.67]	<.0001
Wound complications	290 (120.87)	87 (35.55)	3.45 [2.70, 4.42]	<.0001
Bleeding	172 (70.50)	26 (10.57)	6.87 [4.49, 10.52]	<.0001
<b>Other</b>				
Psychiatric disorder	317 (131.64)	268 (111.93)	1.33 [1.13, 1.58]	0.0008
Alcohol abuse	180 (73.10)	65 (26.52)	2.90 [2.16, 3.88]	<.0001
Cancer	153 (61.80)	188 (77.41)	0.78 [0.63, 0.97]	0.0257
Malnutrition	128 (51.69)	46 (18.72)	2.81 [1.98, 3.97]	<.0001
Kidney disease	105 (42.38)	187 (76.87)	0.58 [0.45, 0.75]	<.0001
Pulmonary complications	86 (34.66)	114 (46.64)	0.84 [0.63, 1.13]	0.249
Anemia	84 (33.78)	46 (18.71)	1.92 [1.33, 2.76]	0.0005
Amputation	15 (5.99)	23 (9.33)	0.51 [0.26, 0.98]	0.0432
Dementia	4 (1.60)	12 (4.87)	0.46 [0.14, 1.57]	0.214

Event rates (%) per 10.000 person-years.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




Figure 1A-F: Cumulative incidence of postoperative outcomes during the 9-years follow up. All-cause mortality; Congestive heart failure; Kidney disease; Malnutrition; Psychiatric disorder; Alcohol abuse.




Figure 2A-F: Cumulative incidence of postoperative adverse events during the 9-years follow-up. Gastrointestinal (GI) surgery; Abdominal pain; Bowel obstruction; Gallstone and gallbladder disease; Wound complications; Plastic surgery


## SUPPLEMENTARY MATERIAL

### Table of contents

- Flowchart – patient selection
- Methods – database linkages
- Table S1. ICD-10 codes
- Table S2. Risk estimates for men and women

### Flowchart

Selection of our data from Scandinavian Obesity Surgery Register (SOReg) before merging with data from the National Diabetes Registry (NDR).



Merging the two databases led to our study population of 5,321 patients in the SOReg who had T2DM and had undergone GBP, and 5,321 matched control patients in the NDR.

### Methods – database linkages

This study is based on data from the NDR and SOReg. Both registers are linked to Statistics Sweden at the National Board of Health and Welfare, which also stores data in the Swedish Inpatient Register (1997-2015).

We filed an application with our data and personal identity numbers [SOReg (2007-2013) & NDR (1996-2015)] to the National Board of Health and Welfare, from which all personal identity numbers have been identified and replaced by serial numbers. The coded data from the National Board of Health and Welfare were subsequently forwarded to Statistics Sweden for linkage with the Inpatient Register and LISA Database, which provides socioeconomic data. The linked data were then returned to us for validation and analysis.

**Table S1: Pre-index diagnoses and outcomes after GBP**

Diagnoses before and after gastric bypass surgery (index date) until December 2015 according to ICD-10.

Diagnosis	ICD-10	Variable origin	Registration period
Acute Myocardial infarction	<i>I21</i>	Swedish Inpatient Register	2007-2015
Coronary heart disease	<i>I20-25</i>	Swedish Inpatient Register	2007-2015
Stroke	<i>I61-64</i>	Swedish Inpatient Register	2007-2015
Cardiovascular disease	<i>I21, I61-64</i>	Swedish Inpatient Register	2007-2015
Atrial fibrillation	<i>I48</i>	Swedish Inpatient Register	2007-2015
Heart failure	<i>I50</i>	Swedish Inpatient Register	2007-2015
Valvular heart disease	<i>I05-09, I34-37, Q22, Q23</i>	Swedish Inpatient Register	2007-2015
Liver disease	<i>K70-74</i>	Swedish Inpatient Register	2007-2015
Kidney disease	<i>V42A, V45B, V56A, V56W, Z940, Z491, Z492, Z992, N17-19, N99</i>	Swedish Inpatient Register	2007-2015
Hyperglycemia	<i>E100, E101, E110, E111, E120, E121, E130, E131, E140, E141, R739</i>	Swedish Inpatient Register	2007-2015
Hypoglycemia (with or without coma)	<i>E100, E106A, E110, E110C, E110X, E116A, E120, E130, E140, E159, E160, E161W, E162, R402</i>	Swedish Inpatient Register	2007-2015
Cancer	<i>C0-9</i>	Swedish Inpatient Register	2007-2015

Dementia	<i>G300, G301, G308, G309, G31, F00-03</i>	Swedish Inpatient Register	2007-2015
Psychiatric disorders	<i>F11-19, F20-29, F30-39, F50, F55, F40-F43, F60, F61, F68, F69, F99</i>	Swedish Inpatient Register	2007-2015
Alcohol abuse	<i>F10</i>	Swedish Inpatient Register	2007-2015
Anemia	<i>D508-9, D51.0,3,8, D520</i>	Swedish Inpatient Register	2007-2015
Malnutrition	<i>E15-16, E51.2, E42-44, E46, E50-64, G63.3-4, G62.9, K91.1-2, M81.3, M83.2</i>	Swedish Inpatient Register	2007-2015
Bleeding	<i>T81.0</i>	Swedish Inpatient Register	2007-2015
Deep vein thrombosis and pulmonary embolism	<i>I80.0-9, I26, I81</i>	Swedish Inpatient Register	2007-2015
Amputation	<i>NHQ09, 11-14, 16, 17, 99, NGQ09, 19, 99, NFQ19, 99</i>	Swedish Inpatient Register	2007-2015
Bowel obstruction	<i>K56, K45</i>	Swedish Inpatient Register	2007-2015
Gastrointestinal leakage	<i>T84.4, K65.0, K63.1</i>	Swedish Inpatient Register	2007-2015
Pulmonary complications	<i>J18.0-9, J69.0, J80, J98.1</i>	Swedish Inpatient Register	2007-2015
Wound complications	<i>T81.3-4, K43.0-9</i>	Swedish Inpatient Register	2007-2015
Gastrointestinal ulcer and reflux	<i>K21, K22.1-3, K25-26, K28</i>	Swedish Inpatient Register	2007-2015
Hernia	<i>K40-43</i>	Swedish Inpatient Register	2007-2015
Gallstone, gallbladder disease and pancreatitis	<i>K80-85</i>	Swedish Inpatient Register	2007-2015
Gastrointestinal surgery not	All the operative diagnoses with	Swedish Inpatient Register	2007-2015





**Table S2: Risk estimates for men and women (Cox proportional hazards regression)**

<b>Outcome</b>	<b>Men HR with 95% CI (n=4024)</b>	<b>Women HR with 95% CI (n=6618)</b>	<b>p-value</b>
All-cause mortality	0.58 (0.45, 0.74)	0.46 (0.35, 0.60)	0.2091
Coronary heart disease	1.14 (0.90, 1.44)	1.12 (0.88, 1.42)	0.9011
Cardiovascular disease	0.63 (0.44, 0.92)	0.69 (0.49, 0.96)	0.7614
Fatal coronary heart disease	0.42 (0.24, 0.73)	0.25 (0.12, 0.54)	0.2853
Fatal cardiovascular disease	0.60 (0.32, 1.14)	0.13 (0.05, 0.36)	0.0118
Acute myocardial infarction	0.55 (0.32, 0.92)	0.56 (0.35, 0.90)	0.9522
Stroke	0.67 (0.32, 1.12)	0.88 (0.55, 1.41)	0.4429
Atrial fibrillation	1.13 (0.86, 1.47)	0.72 (0.53, 0.98)	0.0313
Heart failure	0.63 (0.46, 0.86)	0.35 (0.24, 0.51)	0.0201
Valvular heart disease	0.83 (0.38, 1.84)	0.49 (0.21, 1.13)	0.3645
Hyperglycemia	0.22 (0.09, 0.53)	0.40 (0.23, 0.69)	0.2624
Hypoglycemia with coma	0.79 (0.39, 1.63)	1.21 (0.71, 2.05)	0.3490
Dementia	0.73 (0.19, 2.86)	0.00 (.,.)	0.9991
Kidney disease	0.84 (0.28, 2.54)	0.37 (0.12, 1.13)	0.2995
Amputation	0.82 (0.36, 1.85)	0.16 (0.04, 0.72)	0.0613
Cancer	1.02 (0.69, 1.51)	0.69 (0.53, 0.90)	0.1068
Psychiatric disorder	1.02 (0.76, 1.37)	1.51 (1.23, 1.85)	0.0289
Alcohol abuse	2.87 (1.98, 4.15)	2.94 (1.85, 4.69)	0.9298
Liver diseases	0.53 (0.25, 1.13)	0.92 (0.49, 1.73)	0.2731
Anemia	1.96 (0.96, 4.01)	1.90 (1.24, 2.90)	0.9390

<b>Outcome</b>	<b>Men HR with 95% CI (n=4024)</b>	<b>Women HR with 95% CI (n=6618)</b>	<b>p-value</b>
Bleeding	9.74 (4.69, 20.22)	5.50 (3.26, 9.29)	0.2110
Deep vein thrombosis and pulmonary embolism	1.10 (0.59, 2.03)	0.96 (0.60, 1.55)	0.7455
Bowel obstruction	6.17 (3.33, 11.46)	12.10 (7.10, 20.64)	0.1035
Gastrointestinal leakage	5.28 (1.55, 18.01)	5.73 (1.96, 16.79)	0.9217
Malnutrition	2.72 (1.59, 4.67)	2.86 [1.83, 4.47]	0.8879
Pulmonary complications	0.96 (0.59, 1.56)	0.78 [0.54, 1.12]	0.4915
Wound complications	4.70 (2.79, 7.90)	3.12 [2.36, 4.13]	0.1743
Gastrointestinal ulcer and reflux	5.57 (3.49, 8.89)	5.28 (3.36, 8.31)	0.8719
Hernia	3.53 (2.19, 5.69)	2.47 (1.83, 3.33)	0.2136
Gallstone, gallbladder disease and pancreatitis	2.33 (1.59, 3.41)	2.56 (1.99, 3.30)	0.6810
Gastrointestinal surgery (not gastric bypass)	9.93 (8.35, 11.80)	7.13 (6.37, 7.98)	0.0015
Plastic surgery	16.96 (6.84, 42.07)	20.73 (12.67, 33.92)	0.7024
Abdominal pain	7.22 (4.64, 11.24)	5.12 (4.08, 6.41)	0.1703

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies***

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6,7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6,7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	6, suppl
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8, suppl
		(c) Explain how missing data were addressed	-
		(d) If applicable, explain how loss to follow-up was addressed	-
		(e) Describe any sensitivity analyses	-
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	suppl
		(c) Consider use of a flow diagram	suppl
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8,20,21
		(b) Indicate number of participants with missing data for each variable of interest	-
		(c) Summarise follow-up time (eg, average and total amount)	8
Outcome data	15*	Report numbers of outcome events or summary measures over time	8,9,20,21,22,23
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9,22,23
		(b) Report category boundaries when continuous variables were categorized	9,22,23
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	suppl
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10,11,12,13,14,15
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).